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ABSTRACT
The mammalian target of rapamycin (mTOR) is a crit-
ical regulator of cell growth, integrating multiple sig-
nalling cues and pathways. Key among the down-
stream activities of mTOR is the control of the pro-
tein synthesis machinery. This is achieved, in part,
via the co-ordinated regulation of mRNAs that con-
tain a terminal oligopyrimidine tract (TOP) at their
5′ends, although the mechanisms by which this oc-
curs downstream of mTOR signalling are still un-
clear. We used RNA-binding protein (RBP) capture
to identify changes in the protein-RNA interaction
landscape following mTOR inhibition. Upon mTOR
inhibition, the binding of LARP1 to a number of mR-
NAs, including TOP-containing mRNAs, increased.
Importantly, non-TOP-containing mRNAs bound by
LARP1 are in a translationally-repressed state, even
under control conditions. The mRNA interactome of
the LARP1-associated protein PABPC1 was found to
have a high degree of overlap with that of LARP1 and
our data show that PABPC1 is required for the asso-
ciation of LARP1 with its specific mRNA targets. Fi-
nally, we demonstrate that mRNAs, including those
encoding proteins critical for cell growth and sur-
vival, are translationally repressed when bound by
both LARP1 and PABPC1.
INTRODUCTION
The mammalian target of rapamycin (mTOR) is the cat-
alytic component of two multi-protein complexes known
as mTORC1 and mTORC2 with differing activities depen-
dent upon its interacting partners (1–8). mTORC1 and
mTORC2 are activated by upstream growth signals and
control the balance between catabolic and anabolic pro-
cesses through the phosphorylation of distinct substrates
(reviewed in (9,10)). mTORC1, in particular, plays a major
role in the regulation of protein synthesis (reviewed in (11–
14)). mTORC1 mediated regulation of protein synthesis is
achieved via several mechanisms (12,13). This includes the
control of cap-dependent translation through the phospho-
rylation of the 4E binding proteins (4E-BP1–3 (15,16)) to
regulate eIF4F complex formation, the activation of ribo-
somal protein S6 kinases (S6Ks) (17), which phosphorylate
several substrates involved in translation elongation includ-
ing the ribosomal protein S6 (18–22), and the eukaryotic
elongation factor 2 kinase (eEF2K), which in turn modu-
lates elongation rates through the phosphorylation of the
eukaryotic elongation factor 2 (eEF2) (23).
A major group of co-regulated growth-associated mR-
NAs controlled by mTORC1 are the terminal oligopyrim-
idine tract (TOP) mRNAs, which encode ribosomal pro-
teins and translation factors (24–27). TOP transcripts are
defined by a distinctive motif at the 5′end of these mRNAs,
which start with a cytosine after the m7GTP cap structure,
followed directly by an uninterrupted pyrimidine tract 4–14
nucleosides in length (28–30). This feature is the determi-
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nant that allows rapid and reversible control of the biosyn-
thesis of the translational apparatus via mTORC1 signalling
(31). Ribosome profiling approaches have revealed that a
similar mTOR dependent translational regulation may also
occur on mRNAs that contain a pyrimidine-rich transla-
tional element (PRTE) downstream of the cap in the 5′UTR
(31,32). Both TOP and PRTE regulation occurs in a nutri-
ent and growth factor-dependent manner, allowing for the
highly energy consuming process of ribosome production
to be downregulated when cellular amino acid or energy
levels become limiting. TOP mRNAs are highly stable and
abundant in mammalian cells and the control of their ex-
pression is believed to occur predominantly at the level of
translation (26,33–34). Several candidate trans-acting pro-
teins and micro-RNAs have been previously proposed to
regulate TOP-containing mRNA translation (35–37). Re-
cent studies have identified La-related protein 1 (LARP1)
as a protein that binds to both the m7Gppp-C cap and ter-
minal oligopyrimidine tract (38–42). There has been contro-
versy in the literature regarding whether LARP1 is a nega-
tive or positive regulator of translation. An original study
by Tcherkezian et al. (41) reported that LARP1 stimulated
the translation of TOP mRNAs upon insulin treatment;
however, recent studies have found that rather than activat-
ing their translation, LARP1 represses TOP mRNA trans-
lation (38–40,42–43). The mechanism by which LARP1
causes repression is still incompletely understood, but it has
been demonstrated that LARP1 binds directly to the cap-
structure and adjacent 5′TOP motif of TOP mRNAs, thus
competing with eIF4F complex for accessibility to their
5′UTR (39).
Recent development of a novel class of inhibitors of
mTOR (44–46) that directly target the active site of mTOR
allows for the inhibition of both complexes. Our study
encompasses inhibition of mTORC1 and mTORC2 since
both have been implicated in controlling translation (11–
14,17,47–50) and potentially regulate RNA binding pro-
tein ineractions. mTORC2 is regulated by growth factors
through phosphatidylinositol 3-kinase (PI3K) (5,51–53)
and activity also appears to be stimulated by interaction
with the ribosome in a protein-synthesis independent man-
ner (47,48). mTORC2 phosphorylates and regulates sev-
eral kinases including AKT, PKC and SGK1 (4,6,51,54–
58). The main known functional output of mTORC2 is in
actin cytoskeleton organization (1,4,6).
In this study, we characterized mTOR-regulated reor-
ganization of ribonucleo-protein complexes, to determine
how these proteins were controlling translation and investi-
gate their influence on the life cycle of mRNA. Herein we
used Torin1, a specific pharma-logical inhibitor of mTOR
(mTORC1 and mTORC2) (45,46,59) in conjunction with
whole cell RNA-binding protein capture to identify mTOR
regulated mRNA trans-acting factors. This work led to
the identification of 22 RNA-binding proteins differentially
binding to RNA following mTOR inhibition with LARP1
and TRIM25 increasing their binding. Furthermore we
characterized the RNAs that are bound to LARP1 and how
the binding changes upon mTOR inhibition. We examined
the properties of these mRNAs with regard to translation
and present data to show that PABPC1 interaction is re-
quired for LARP1 binding specificity.
MATERIALS AND METHODS
Chemicals and reagents
Unless stated otherwise, all chemicals were purchased from
Sigma-Aldrich or ThermoFisher Scientific. Torin1 was pur-
chased from Tocris Bioscience (catalogue # 4247). Protein
A/G plus agarose was purchased from Santa Cruz Biotech-
nology (catalogue # SC-2003). RNasin Plus RNase In-
hibitor was purchased from Promega (catalogue # N2615).
The following antibodies were used: Rabbit IgG (Santa
Cruz Biotechnology, catalogue # SC2027); AKT (P) Ser473
(Cell Signalling Technologies, catalogue # 4060); S6K (Cell
Signalling Technologies, catalogue # 2708); S6K (P) Thr389
(Cell Signalling Technologies, catalogue # 9234); RPS6
(Cell Signalling Technologies, catalogue # 2217); RPS6
(P) Ser240/244 (Cell Signalling Technologies, catalogue #
2215); 4E-BP1 (P) Thr37/46 (Cell Signalling Technologies,
catalogue # 9459); 4E-BP1 (P) Ser65 (Cell Signalling Tech-
nologies, catalogue # 9451); 4E-BP1 (Cell Signalling Tech-
nologies, catalogue # 9644); eIF4E (Novus Biologicals, cat-
alogue # NBP1–0058833); eIF4G (Cell Signalling Tech-
nologies, catalogue # 2498); -tubulin (Santa Cruz Biotech-
nologies, catalogue # SC-9104); GAPDH (Santa Cruz
Biotechnologies, catalogue # SC-32233); PABPC1 (kind
gift from Professor Simon Morley); hnRNP-Q (Novus Bi-
ologicals, catalogue # NBP1–07043); PSF (Santa Cruz
Biotechnology, catalogue # SC-101137); PTBP1 (Ther-
moFisher Scientific, catalogue # 32-4800); LARP1 (Novus
Biologicals, catalogue # NBP1–19128); PWP2 (Atlas An-
tibodies, catalogue # HPA024573); SERBP1 (Bethyl Labs,
catalogue # A303-938A); TRIM25 (Abcam, catalogue #
ab167154); RPS10 (GeneTex, catalogue # GTX101836).
Cell culture and treatment
HeLa cells were cultured in 4.5 g/l glucose DMEM
(GIBCO Invitrogen Life Technologies catalogue # 21969-
035) supplemented with 2 mM L-glutamine (GIBCO Invit-
rogen Life Technologies catalogue # 25030032) and 10%
(v/v) foetal bovine serum (GIBCO Invitrogen Life Tech-
nologies catalogue # 10270-106) in a humidified, 5% (v/v)
CO2 incubator at 37◦C in the absence of antibiotics. Cells
were routinely mycoplasma tested and also underwent cell
line authentication using the GenePrint 10 kit (Promega,
catalogue # B9510) and data was analysed using Applied
Biosystems Genemapper v4.1 software. Prior to drug treat-
ment, medium was supplemented with an extra 2% (v/v)
foetal bovine serum and 2 mM L-glutamine for 30 min.
Treatments were performed by the addition of 200 nM
Torin1 or equivalent volume of DMSO vehicle (control) for
60 min prior to cell lysis.
Whole cell RNA-binding protein (RBP) capture using
oligo(dT) affinity isolation
Nine 15cm plates of HeLa cells were seeded at 1.8 mil-
lion cells per plate per treatment. Twenty-four hours post-
plating, cells were treated for 1 h ± 200 nM Torin1 as above.
Medium was then aspirated and the cells washed twice with
8 mL ice-cold PBS. Plates were irradiated at 150 mJ/cm2 on
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ice in a 254 nm UV oven. Cells were lysed directly by scrap-
ing on the plate by adding 2 ml of oligo(dT) lysis/binding
buffer (20 mM Tris pH7.4, 500 mM LiCl, 0.5% (w/v) LiDS,
1 mM EDTA, 5 mM DTT and protease inhibitor tablet) at
room temperature. Lysates for each condition were pooled
and passed through a 21G needle 10 times, followed by in-
cubation at room temperature for 10 min with end-over-
end rotation. Lysates centrifuged briefly at room tempera-
ture. Meanwhile, 0.5 ml magnetic oligo(dT) beads per 2 ml
lysate were equilibrated in 1 ml lysis buffer with end-over-
end rotation at room temperature for 5 min. Using a mag-
netic rack, buffer was removed and beads resuspended in
1.95 ml lysate. Remaining lysate was used as input sample.
Pull-downs were incubated at room temperate for 1 h 15 min
mixing end-over-end on a rotating wheel. Using a magnetic
rack, the non-bound fraction was removed and beads were
then washed twice for 10 min with constant rotation in 950
l of wash buffer I (20 mM Tris pH 7.4, 500 mM LiCl, 0.1%
(w/v) LiDS, 1 mM EDTA, 5 mM DTT), centrifuged briefly
and then twice for 5 min with constant rotation in 950 l of
wash buffer II (20 mM Tris pH 7.4, 500 mM LiCl, 1 mM
EDTA), and centrifuged briefly again. Beads were resus-
pended gently 2–3 times in 0.5 ml of LS buffer (20 mM Tris
pH 7.4, 200 mM LiCl, 1 mM EDTA) and incubated at room
temperature for 5 min without rotation. Using a magnetic
rack, LS buffer was removed and beads centrifuged at 3000
rpm for 10 s and residual LS buffer was removed. Beads
were re-suspended in 60 l of elution buffer (20 mM Tris pH
7.4, 1 mM EDTA) per tube and incubated at 92◦C for 4 min,
with shaking at 450 rpm. Tubes were placed in a magnetic
rack and supernatants pooled into fresh 2 ml tubes. The elu-
tion step was repeated and eluates were pooled with first elu-
tion for each condition and RNA concentration measured
using a NanoDrop. RNA was then sodium acetate/ethanol
precipitated. Pellets were resuspended in 45–55 l elution
buffer plus 1 mM MgCl2, 125 U Benzonase (Sigma-Aldrich
catalogue # E104-25KU) and 300 U RNase I (Ambion cat-
alogue # AM2295). Samples were incubated at 37◦C for 2
h to digest the RNA. 5× SDS PAGE loading buffer was
added to the samples.
Sample preparation and mass spectrometry
Samples were subjected to SDS-PAGE and gels were
stained in ProtoBlue™ Safe Colloidal Coomassie Blue G-
250 stain (National Diagnostics) as per manufacturer’s in-
structions. Gels were then prepared for mass spectrome-
try analysis as follows: lanes were equally sectioned and
gel slices were alternately washed in 50 mM NH4HCO3
and 100% (v/v) acetonitrile three times. Samples were re-
duced in 10 mM dithiothreitol (for 20 min, 56◦C) and alky-
lated in 100 mM iodoacetamide, prior to rinsing in 50 mM
NH4HCO3/100% (v/v) acetonitrile. Gel pieces were soaked
in trypsin digestion buffer (25 mM NH4HCO3 containing
11.11 g/ml of Modified Trypsin (Promega Corporation,
USA)). Digests were incubated overnight at 30◦C. Triflu-
oroacetic acid was added to each digest at 0.2% (v/v) fi-
nal concentration and reactions incubated for 1 h at room
temperature to extract protein. Samples then lysophilized
in a Savant DNA Speed Vac (Thermo Scientific, USA).
Lysophilized peptides then resuspended in 5% (v/v) formic
acid/acetonitrile at a ratio of 9:1. Samples were spiked with
two standards, yeast ADH1 (P00330) and bovine serum al-
bumin (P02769) (MassPREP standards, Waters Corpora-
tion, UK) to a final concentration of 20 fmol/l. Peptides
were then separated by nanoflow liquid chromatotgraphy
coupled to a Synapt G2S mass spectrometer for analysis
(NanoAcquity UPLC system and Synapt G2S mass spec-
trometer, Waters Corporation, UK), using a 25 cm by 75
m I.D., 1.7 m BEH130 C18 column. 2 l sample in-
jections were separated using a 90 min reversed phase, 3–
40% (v/v) acetonitrile gradient, run at 0.3 l/min. Mass
spectrometry analysis was performed in a data-independent
manner, using ion mobility HDMSE, with IMS wave veloc-
ity in the helium cell set to 650 m/s. The mass spectrome-
ter stepped between 4 eV (low energy) and 20–50 eV (ele-
vated collision energy) in the gas cell, with a scan time of
1 second and a mass range of 50–2000 m/z. Protein identi-
fications and absolute quantification information were ex-
tracted from the raw data files using ProteinLynx Global
Server (PLGS version 3, Waters Corporation, UK) in com-
bination with ISOQuant (Kuharev and Tenzer, Germany,
open source under http://www.immunologie.uni-mainz.de/
isoquant/). Data was then processed with energy thresh-
olds set to 135 and 30. The human UniProt database, in-
cluding reverse sequences (UniProtKB/SwissProt, release
2014 05, 11.06.2014, 20265 entries) was used in PLGS, with
peptide mass tolerance and fragment mass tolerance set to
automatic, with an allowed maximum of one missed cleav-
age. Ion matching requirements set to one or more frag-
ments per peptide, three plus fragments per protein and one
or more peptides per protein, with a False Discovery Rate
(FDR) of 1%. Processed, database searched PLGS data files
were loaded into ISOQuant for quantitative analysis using
an FDR of 0.1%, only returning an absolute fmol amount
of protein if three reliable peptide hits were available for
quantification (TOP3 method). This software used first past
matches, thereby ignoring any peptides generated by in-
source fragmentation or modified peptides. ADH1 internal
standards were used to calculate absolute amounts of iden-
tified proteins. Software did not identify splicing isoforms
of proteins independently of one another, instead identify-
ing them as a single protein based on peptides. Data from
TOP3 ISOQuant analysis was exported to excel for further
fold-change and statistical analysis. Non-human spike-ins
and proteins with missing observations were removed. The
resulting list of 214 proteins were adjusted for batch effects
using the SVA package (60) in R. Statistical analysis was
then performed using the openly available limma Biocon-
ductor package (61). Method adapted from (62).
Endogenous immunoprecipitation of LARP1 or PABPC1
HeLa cells were seeded at 1.8 × 106 per plate. After 24 h,
the media was supplemented with 2% (v/v) foetal bovine
serum, 2mM L-glutamine for 30 min followed by 1 h with
DMSO or 200 nM Torin1. Meanwhile, protein A/G beads
were pre-coupled to antibodies as follows; using 100 l bead
slurry (Protein A/G plus agarose SC-2003) per IP: bead
slurry was washed twice with 1 ml IP lysis buffer (20 mM
Tris–HCl pH 7.5, 150 mM NaCl, 15 mM MgCl2, 0.5%
(v/v) nonidet P40/Igepal, 1 mM EDTA, 0.5% (w/v) sodium
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deoxycholate, 0.1% (v/v) 2-mercaptoethanol, protease in-
hibitor cocktail tablet (Roche Applied Sciences catalogue
# 11836170001), 1 mM -glycerophosphate, 1 mM sodium
fluoride and RNasin Plus RNAse inhibitor (40 U/ml)) and
resuspended to initial volume. Beads were pre-coupled in
IP lysis buffer with 3 g per IP of either Rabbit IgG (0.4
g/l), PABPC1 antibody (1 g/l) or LARP1 Antibody
(0.2 g/l) for 2 h at 4◦C with end-over-end rotation. Pre-
incubated beads were spiked with 1:100 (v/v) yeast tRNA
for 30 min at 4◦C. Beads then washed three times with 1
ml of lysis buffer and 100 l beads used per IP. Following
treatments, cells were washed twice with 8 ml volume of PBS
then lysed in 2 ml of IP lysis buffer per plate. Where RNase I
was used (Supplementary Figure S9), 150 U/ml was added
to the lysis buffer prior to lysis (and RNasin Plus RNase
inhibitor was not added). Lysates were passed through a
21G needle three times before equilibration by end-over-
end rotation for 5 min at 4◦C. Lysates were then spun down
for 15 min at 4◦C at 13 000 rpm, supernatants collected
and pooled. Protein concentration determined by Bradford
and lysates normalized for protein concentration. 100 l
of lysate reserved for western and 100 l for input RNA
(added to 1 ml TRIzol Reagent (from Thermo Fisher Sci-
entific catalogue # 15596018)). Beads were incubated with
1.5 ml normalized protein extract at 4◦C with end-over-end
rotation for 90 min. Beads washed four times for 5 min with
end-over-end rotation with 1 ml of lysis buffer. At the last 1
ml wash: beads were pooled for each treatment and split for
RNA and protein analysis: 200 l for protein analysis- cen-
trifuged briefly, supernatant removed and resuspend in 60
l 1× sample buffer; 800 l for RNA analysis- wash buffer
was removed and 1 ml of Trizol was added. RNA extraction
was then performed as described below.
RNA extraction
RNA extraction was carried out using Trizol reagent (from
Thermo Fisher Scientific catalogue # 15596018) follow-
ing the manufacturer’s instructions. Glycogen was used as
a carrier to aid RNA precipitation. Trizol extraction was
followed by phenol: chloroform extraction and overnight
sodium acetate/ethanol precipitation at –20◦C.
Endogenous immunoprecipitation of LARP1 with UV254
cross-linking
HeLa cells were seeded and treated as for endogenous IPs.
Following treatments cells were washed twice with 8 ml vol-
ume of PBS. Plates (with no lid or PBS) were placed on
a tray of ice in 254 nm UV oven and irradiated at 150
mJ/cm2 (two plates at a time). 2 ml of IP lysis buffer was
added per plate and lysates were collected as for endogenous
immunopreciptations above. Protein concentration was de-
termined by Bradford Assay and lysates normalized for pro-
tein concentration. 100 l of lysate was reserved for western
blotting and 100 l for input RNA (treated as mentioned
later). Protein A/G beads precoupled to antibodies were
spun down and resuspended in 100 l lysis buffer per treat-
ment. 100 l aliquots were made for IPs and 12 l tRNA
was spiked into each tube. Lysates were incubated with indi-
cated antisera coupled beads at 4◦C on a wheel for 90 min.
Beads were washed twice for 5 min with end-end rotation
with 1 ml high salt buffer (20 mM Tris–HCl pH 7.5, 350 mM
NaCl, 15 mM MgCl2, 0.5% (v/v) IGEPAL, 1 mM EDTA,
0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS). Beads
were then washed twice for 5 min with end-end rotation with
1 ml iso buffer (20 mM Tris–HCl pH 7.5, 150 mM NaCl, 15
mM MgCl2, 1 mM EDTA and 7 mM -mercaptoethanol).
At last, 1 ml wash beads were pooled for each treatment and
split for RNA and protein analyses: 700 l for RNA and
240 l for protein. Supernatants were removed and beads
for RNA analysis resuspended in 100 l proteinase K so-
lution (iso buffer containing 80 U/ml RNasin Plus RNAse
inhibitor, 1% (w/v) SDS and 200 g/ml proteinase K (In-
vitrogen catalogue # 25530049). 100 l of each input were
also proteinase K treated by adding 200 g/ml proteinase
K solution. Samples were incubated at 37◦C for 40 min
with shaking at 800 rpm then added to 1 ml Trizol LS and
frozen at –80 prior to RNA extraction. Beads for protein
analysis were re-suspended in 55 l iso buffer. Premixed
RNAse/DNAse (50 U Benzonase, 50 U RNase I and 50U
RNAse A) was added and incubated at 37◦C for 2 h to di-
gest RNA. One hundred microlitres of each input was also
incubated with 50 U of the RNAses. 20 l 5× SDS PAGE
loading buffer was added to IPs and 40 l to inputs for west-
ern blot analysis.
Transient transfection and flag pulldowns
HeLa cells were seeded at 1.6 × 106 per plate. After 24 h,
cells were transfected with 5 g of vector (as indicated in fig-
ure legends). Twenty four hours following transfection cells
were Torin1/DMSO treated, harvested, lysed and cleared
supernatants prepared and normalized for protein concen-
tration as for endogenous IPs (above). Normalized lysates
were incubated with end-end rotation with 50 l Anti-
FLAG® M2 magnetic beads (Sigma-Aldrich catalogue #
M8823) for 90 min at 4◦C. Beads were then washed 4 times
for 5 min in IP lysis buffer (buffer as described for endoge-
nous IPs). At the last 1 ml wash beads were split for RNA
and protein analysis as described in the endogenous IP pro-
tocol above. For competitive elution, performed for Flag
RNA binding protein experiments shown in Supplementary
Figure S2: Immunorecipitations were performed as above,
with the exception that following the fourth wash, beads
were resuspended in 100 ul of Flag elution buffer (IP lysis
buffer containing 200 ng/ul 3× FLAG® peptide (Sigma-
Aldrich catalogue # F4799) and elution performed as man-
ufacturers protocol. Eluates were split for RNA and protein
analysis as described previously in the endogenous IP pro-
tocol.
mRNA arrays and analysis
Resuspended RNA from endogenous pulldowns was la-
belled and hybridized to 60K human gene expression
whole genome microarrays (Agilent Technologies, Berk-
shire, UK), following the manufacturer’s protocol and as
described (63). 100 ng input RNA, and the contents of
10 l IP RNA (from a total of 25 l) was Cy-3 labelled
using Agilent Low Input Quick Amp 1-colour Labelling
Kit (Agilent). The level of dye incorporation was measured
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using a Nanodrop ND1000 spectrophotometer (LabTech,
Sussex, UK). 600 ng Cy-3 labelled input sample, 600 ng
Cy-3 labelled IP mRNA (antibody-treated samples) and
the equivalent volumes of vehicle control samples were
taken and all fragmented using fragmentation buffer from
the Agilent Gene Expression Hybridization Kit (Agilent)
for 30 min at 60◦C. Fragmented samples were mixed 1:1
with Hybridization Buffer (v/v) and hybridized to a 60K
high-density oligonucleotide microarray overnight (G4858-
039494 (Agilent SurePrint G3 Human GE v2 8 × 60K
Microarray 039381 (Feature Number version)). Microar-
rays were loaded as per the manufacturer’s instructions and
hybridization was performed at 65◦C, in an Agilent Hy-
bridization Oven with rotation set to 10 RPM. Following
hybridization, the microarray slides were washed in Gene
Expression wash buffers 1 and 2 (Agilent) and immedi-
ately scanned using a DNA Microarray Scanner (Model
G2505C, Agilent Technologies). Array analysis performed
using limma, using normalized expression background cor-
rection, quantile normalization, filtered for spots with in-
tensity >1.5 of negative control probes, FDR <0.05 ap-
plied to linear model fitting. Enrichment in the IPs was
calculated as fold change of signal in the immunoprecipi-
tated sample versus the corresponding input RNA samples.
Those mRNAs considered to be enriched in the IP had a log
FC > 0.5 and FDR < 0.05. RNAs binding to LARP1 or
PABPC1 were divided into the following groups for subse-
quent analysis: ‘induced bound’: log FC ≤ 0 in control and
log FC > 0.5 in Torin1-treated; ‘constitutively bound’: log
FC > 0.5 in both control and Torin1-treated, ‘unbound’:
log FC < 0 FDR < 0.05 in both control and Torin1 con-
ditions. For Figures 2E and 5F and Supplementary Figure
S5, to provide comparable groups to constitutively bound
and induced bound mRNAs, unbound mRNAs were fur-
ther broken down into ‘constitutively depleted’: log FC <
–0.5 in control and Torin1-treated and ‘induced depleted’:
FDR>0.05 in control and log FC < –0.5 in Torin1-treated.
Polysome sucrose density gradient centrifugation and frac-
tionation for RNA analysis
HeLa cells were cultured and treated as previously and in-
cubated with 0.1 mg/ml cycloheximide at 37◦C 3 min prior
to lysis, rinsed twice in PBS containing 0.1 mg/ml cyclo-
heximide and scraped into chilled lysis buffer (15 mM Tris–
HCl pH 7.5, 0.3 M NaCl, 15 mM MgCl2, 0.1 mg/ml cy-
cloheximide, 1 mg/ml heparin and 1% Triton-X-100). Cell
lysates were then placed on ice for 10 min to allow lysis to
occur. Nuclei and cell debris were removed by centrifuga-
tion at 4◦C for 5 min at 13 000 rpm. Supernatants were then
loaded onto 10–50% sucrose gradients (containing 15 mM
Tris–HCl (pH 7.4), 15 mM MgCl2, 0.15M NaCl, 0.1 mg/ml
cycloheximide, and 1 mg/ml heparin) in Sorvall PA 12 ml
tubes. Gradients sedimentation was performed at 38 000
rpm for 2 h in an SW40Ti at 4◦C. Sucrose gradients were
fractionated at 1 ml/min on an ISCO fraction collector ap-
paratus. 1 ml fractions were collected directly into 3 ml 7.7
M guandine–HCl and the RNA precipitated by addition of
4 ml volume of 100% ethanol. The RNA was resuspended
in water and further purified by 2.5 M LiCl precipitation
followed by sodium acetate/ethanol precipitation.
Polysome sucrose density gradient centrifugation and frac-
tionation for analysis of protein distribution
HeLa cells were transiently transfected with 5 g per
plate Flag tagged LARP1 2-1019 wild type (WT), PAM2
L423A/F428A double point mutant (PAM2M), or bacte-
rial alkaline phosphatase (BAP) flag tagged control con-
structs. Twenty-four hours following transfection, medium
was supplemented with 2% serum, 2 mM L-Glut for 30 min
followed by 1 h with DMSO (Control) or 200 nM Torin1.
Cells were treated with 100 g/ml cycloheximide for the last
3 min prior to lysis. After PBS/cycloheximide washes cells
were scraped into chilled hypotonic lysis buffer (5 mM Tris–
HCl pH 7.5, 1.5 mM KCl, 2.5 mM MgCl2, 0.1 mg/ml cyclo-
heximide, 0.5% (v/v) Triton-X-100, 0.5% (w/v) sodium de-
oxycholate with 0.1% (v/v) 2-mercaptoethanol, protease in-
hibitors (Roche Applied Sciences catalogue # 11836170001)
and 40 U/ml RNasin Plus RNase). Nuclei and cell debris
were removed by centrifugation at 4◦C for 5 min at 13 000
rpm. Supernatants were then loaded onto 10–50% sucrose
gradients made up in buffer containing 20 mM HEPES–
KOH pH 7.5, 100 mM KCl, 5 mM MgCl2, 100 g/ml cyclo-
heximide. Gradient sedimentation and fractionation were
performed as with RNA polysome gradient method. West-
ern blotting was performed on each fraction.
Ribosome profiling analysis
Translational efficiency (TE) data from (43) was sorted
into LARP1 RIP mRNA groupings: constitutively bound
(larp constitutive), mTOR inhibition induced bound
(larp induced) and unbound mRNAs, for each of four
conditions: wild type (WT) or LARP1 knockout (KO)
HEK293T cells with either control (DMSO) or Torin1
treatment. This analysis was also performed for LARP1–
PABPC1 bound mRNAs. Ribosome occupancy for LARP1
and PABPC1 bound mRNA groupings was calculated from
ribosome profiling data for three replicates in HEK293
cells in control conditions, obtained from Wilczynska and
Gillen (64). Figures 3D and 5F show normalized ribosome
occupancy. This is the ribosome protected fragments
(RPFs) at each codon position normalized for mRNA
abundance for indicated mRNA groups. To get a global
view across the whole CDS, the RPF coverage across each
transcript CDS has been length normalized.
RT-qPCR
RNA was reverse transcribed by using SuperScript III
(Invitrogen) and Random primers (Invitrogen). Real-time
PCR was carried out by using the Applied Biosystems 7500
Fast Real-Time PCR System and Fast SYBR™ Green Mas-
ter Mix (Applied Biosystems) using the manufacturer’s pro-
tocol. Gene specific primers used are shown in Supplemen-
tary Table S4.
SDS-PAGE and western blotting
Protein samples were subjected to SDS-PAGE using the
Bio-Rad protein mini gel system using resolving gels of
10%, 12% or 15% (w/v) acrylamide depending on the sizes
of the proteins being blotted. Proteins were transferred from
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gels onto 0.4 m nitrocellulose membrane using the Bio-
Rad protean II wet transfer system at 100 V for 2 h. Mem-
branes were then blocked in TBS-Tween 5% (w/v) milk for
30 min to 1 h. Primary antibodies were used at the recom-
mended dilutions in TBS–Tween 5% milk (w/v) for total
antibodies and TBS–Tween 5% BSA (w/v) for phospho-
antibodies. IRDye® conjugated secondary antibodies (LI-
COR) were used at a dilution of 1:10 000 and western blots
were imaged using the LI-COR Odyssey imaging system
and were analysed using Image Studio software Version 2.1.
Silver staining of SDS-PAGE gels
SDS-PAGE gels were rinsed in water and then fixed for
2 h (50% (v/v) EtOH, 12% (v/v) Acetic Acid, 0.05%
(v/v) formaldehyde), washed for 3 × 15 min in 50% (v/v)
EtOH, put into sensitization solution for 1 min (0.02%
(v/v) Na2S2O3), washed twice in water followed by 20
min in staining solution (0.2% (w/v) AgNO3, 0.075% (v/v)
formaldehyde), washed twice in water for 30 s followed
by 5–15 min in development solution (3% (v/v) Na2CO3,
4 mg/l Na2S2O3, 0.05% formaldehyde). Developing was
halted using 1% (w/v) glycine for 30 min followed by wash-
ing with water. Gels were imaged using a LI-COR Odyssey
imager and Image Studio software.
Coomassie staining of SDS-PAGE gels
SDS-PAGE gels were placed into 10mL of InstantBlue™
(Sigma ISB1L) for 1–16 h with gentle rocking. Gels were
then rinsed for 4 × 15 min before imaging on the LI-
COR Odyssey system. Gels used for mass spectrometry
were stained as detailed in the sample preparation and mass
spectrometry methods section.
m7GTP pulldowns
50 l of m7GTP-agarose (Jena Bioscience catalogue #
AC-155L) per pulldown was gently centrifuged, storage
buffer aspirated and beads resuspended in an equal vol-
ume of m7GTP lysis buffer (50 mM MOPS/KOH pH7.2,
50 mM NaCl, 2 mM EGTA, 5 mM EDTA, 7 mM
-mercaptoethanol, 50 mM -glycerophosphate, 50 mM
NaF, 1% (v/v) IGEPAL, 1% (v/v) Triton-X-100, pro-
tease inhibitor tablet (Roche Applied Sciences catalogue #
11836170001)). 600 l of each normalized lysate was incu-
bated with 50 l of m7GTP-agarose (pre-equilibrated in ly-
sis buffer). Pulldowns were performed for 1 h at 4◦C with
end over end rotation. Beads were gently pelleted for 20 s at
4000 rpm, the supernatant removed and 1 ml wash buffer
added ((50 mM MOPS/KOH pH 7.2, 50 mM NaCl, 2 mM
EGTA, 5 mM EDTA, 7 mM -mercaptoethanol, 50 mM
-glycerophosphate, 50 mM NaF). The wash step was re-
peated twice and beads were resuspended in 70 l sample
buffer and heated at 95◦C for 5 min prior to running on
SDS-PAGE gels and western blotting.
Northern blotting
DNA probes for northern blotting were generated from
HeLa cDNA by Taq polymerase PCR using the primers
listed in Supplementary Table S4 (where (N) designates
northern probe primers). DNA was gel extracted using the
QIAquick gel extraction kit (Qiagen) as per the manu-
facturer’s protocol. For northern blotting RNA was sub-
jected to size separation on an RNAse free 1% agarose
formaldehyde–MOPS gel alongside 2 and 10 kb RNA
markers. RNA was passively transferred to zeta probe
membrane (Bio-Rad) in 20x SSC buffer (3 M NaCl, 0.3
M sodium citrate solution). RNA was cross-linked to the
membrane using 254 nm Stratalinker set on 1200. The mem-
brane was stained in methylene blue solution (0.02% (w/v)
methylene blue and 0.3 M Na acetate (pH 5.2)) and then
washed several times in water, followed by several washes
in 1× SSC containing 1% SDS and two rinses in wa-
ter. Northern blots were pre-hybridized in 5 ml Church–
Gilbert’s solution at 65◦C for 30 min in a hybridization
oven. Meanwhile, 50 ng of DNA probes were then radi-
olabelled with P32 dCTP using Klenow enzyme (New
England Biolabs). Probes were then passed through G-50
columns (GE Healthcare) to remove unincorporated nu-
cleotides. Filtered probe was denatured, cooled and 25 l
of end-labelled probe added to Church-Gilberts Solution
(140 mM Na2PO4, 70 mM NaH2PO4, 7% SDS) and each
blot incubated in a hybridization oven overnight at 65◦C.
Blots were then washed by rotation for 15 min at RT twice
in each of three wash solutions: Wash solution 1 (2× SSC,
0.1% SDS); Wash solution 2 (0.5× SSC, 0.1% SDS); Wash
solution 3 (0.1× SSC, 0.1% SDS). Blots were then wrapped
in cling film and placed in a developing cassette with a blank
imaging plate overnight. Blots were visualized on a phos-
phorimager.
Cloning and DNA overexpression constructs
cDNA was made from HeLa cells by Trizol extraction of
RNA followed by reverse transcription. Generated cDNA
was then used as a template to amplify SERBP1, TRIM25
and PWP2 using Phusion high fidelity DNA polymerase
(New England Biolabs) and primers listed in Supplemen-
tary Table S5. SERBP1 and PWP2 were cloned into LEICS-
12 N-HIS10/3× Flag vector and TRIM25 was cloned
into LEICS-49 C-HIS4/3× Flag by the University of Le-
icester protein expression laboratory. LARP1 was sub-
cloned from pCMV5-LARP1 (NM015315.3) into p3xFlag-
CMV™-7.1 expression vector (Sigma-aldrich E4026) (re-
striction digested using Hind3 and XBA1 followed by gel
extraction and ligation, to produce n-terminal Flag-tagged
LARP1 purposefully omitting the initiating methionine.
The primers used are listed in Supplementary Table S5.
p3xFlag-CMV™-7-BAP control expression vector was pur-
chased from Sigma (C7472). For generation of pET-SUMO
PABPC1, cDNAs coding for PABPC1 (1–636) were gener-
ated using standard PCR using PABPC1 primers listed in
Supplementary Table S5. PCR product was subsequently
cloned into pET-SUMO vector using the BsaI and NotI re-
striction sites. All CDS open reading frames were sequenced
fully for each construct.
Site directed mutagenesis
Site directed mutagenesis was performed using
Quickchange lightning (Agilent) according to the manufac-
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turer’s protocol. Primers used for mutagenesis are shown
in Supplementary Table S5. PCRs were Dpn1 treated
and used to transform E. coli DH5. For the LARP1
R840E/Y883A double point mutant, mutagenesis was
performed sequentially post sequencing of the correct
clone.
Generation of RPS16 promoter and 5′UTR destabilized fire-
fly luciferase constructs
Initial RPS16 TOP reporter containing the promoter ele-
ment and whole 5′UTR fused to firefly luciferase pGL3-
enhancer vector backbone was a kind gift from Anders
Lund (initial construct described (65)). The region contain-
ing these elements was amplified and inserted into a pGL3
vector modified in the 3′UTR to contain 14× MS2-repeats
between Bsa1/BsrG1 sites. The parental vector was con-
structed using MS2 sites that were PCR amplified from
pSL1180-MS2-12X (66) (a kind gift from Prof. Robert H.
Singer, Albert Einstein College of medicine, Yeshiva Uni-
versity.) and inserted between two existing MS2 sites using
EcoR1/NHE1 restriction sites as described (67). To gener-
ate a faster turnover luciferase protein, destabilization el-
ements hCL1 and hPEST were cloned into the c-terminus
of the ORF from the pGL4.12 vector (Promega E6671) by
firstly performing PCR using pfu turbo (Agilent) and the
following primers with the pGL4.12 template:
hCL1 for - CAAGAAGGGCGGCAAGATCGCCGT
GAATTCTGCTTGCAAGAACTGGTTCAG
PEST rev - GGATCCCCCCTAGAGTATTACTCTAG
AATTAGACGTTGATCCTGGCGCTGGCG
The 233 bp product was then gel extracted and used
as a megaprimer in a second PCR reaction using the
Quickchange lightning kit (Agilent 210519) and the RPS16
TOP reporter as template. Reactions were then Dpn1
treated and transformed into E. coli. Miniprep DNA ex-
tracted and sequenced. The resulting plasmid is known as
Pgl3 RPS16 WT TOP hCL1 PEST. RPS16 MUT TOP
hCL1 PEST was generated by site directed mutagenesis us-
ing the RPS16 MUT for and rev primers in Supplemen-
tary Table S5 to generate a mutant that no longer con-
tained the TOP motif and C-cap: CCUUUUCC but instead
GAGUGACC.
Recombinant protein production
Recombinant human full length LARP1 (1–1096) was ex-
pressed and purified from E. coli at Viva Biotech using
the following protocols. His 6-TEV-LARP1 (1–1096) was
codon optimized and cloned into pET21a (Novagen) via the
NdeI/XhoI restriction sites. pET21a-His 6 -TEV-LARP1
(1–1096) was transformed into BL21 (DE3) GOLD and
grown on LB agar with 100 g/ml ampicillin and incu-
bated at 37◦C overnight. A colony was used to inoculate a
starter culture in LB media (supplemented with 100 g/ml
ampicillin) and incubated overnight at 37◦C with shaking
(220 rpm). Cultures were expanded in Terrific Broth (500
ml), supplemented with 100 g/ml ampicillin, and were in-
cubated at 37◦C with shaking (220 rpm). When cultures
reached an OD600 of 0.6, the temperature was reduced to
18◦C and protein induced for 16 h with 0.5 mM IPTG. Cells
were harvested by centrifugation at 4000 g for 20 min. Cell
pellets were flash frozen in liquid nitrogen and stored at –
80◦C. All purification steps were performed on ice or at 4◦C.
Cell pellets (typically ∼ 100 g) were resuspended at 10%
(w/v) in Lysis Buffer (50 mM Tris–HCl pH 7.5, 500 mM
NaCl, 20 mM imidazole, 10% (v/v) glycerol, Complete Ul-
tra EDTA-free protease inhibitor tablets (used as manufac-
turer’s instructions – Roche Applied Sciences catalogue #
11836170001)) and Benzonase ((Sigma-Aldrich catalogue #
E104-25KU) 1 l per 10 ml of Lysis Buffer). Lysates were
sonicated and clarified by centrifugation at 47 000 g for 1
h followed by filtration through a 0.2 m filter. The super-
natant was loaded onto 2 × 5 ml HisTrap HP columns, pre-
equilibrated with Loading Buffer (50 mM Tris–HCl pH 7.5,
500 mM NaCl, 10% glycerol, 20 mM imidazole). The col-
umn was washed with 10 column volumes (CV) of Load-
ing Buffer followed by 25 CV of High Salt Buffer (50 mM
Tris–HCl pH 7.5, 1 M NaCl, 10% glycerol, 20 mM imida-
zole). The column was finally washed with 5 CV of Low Salt
Buffer (50 mM Tris–HCl pH 7.5, 150 mM NaCl, 10% (v/v)
glycerol, 20 mM imidazole). His-TEV-LARP1 was eluted
from the column using 5 CV of 50 mM Tris–HCl pH 7.5,
150 mM NaCl, 10% glycerol, 300 mM imidazole. Fractions
containing His-TEV-LARP1 were pooled and diluted 1 in 5
with Heparin A Buffer (50 mM Tris–HCl pH 7.5, 10% glyc-
erol, 1 mM DTT). Diluted protein sample was loaded onto
2 × 5 mL HiTrap Heparin HP columns, pre-equilibrated
with Heparin Running Buffer (50 mM Tris–HCl pH 7.5,
40 mM NaCl, 10% glycerol, 1 mM DTT). The column was
washed with 30 CV of this buffer followed by elution us-
ing a linear salt gradient of 40 mM to 1 M NaCl in Heparin
Running Buffer over 25 CV. Fractions containing His-TEV-
LARP1 were pooled and concentrated to approximately 1–
2 ml using a Millipore 30 kDa MWCO centrifugal concen-
trator. This sample was loaded onto a HiLoad 16/600 Su-
perdex 200 column, pre-equilibrated with SEC Buffer (50
mM Tris–HCl pH 7.5, 500 mM NaCl, 10% glycerol, 1 mM
DTT). Following identification by SDS-PAGE analysis, the
His-TEV-LARP1 containing fractions were pooled, flash
frozen in liquid nitrogen and stored at –80◦C.
Recombinant human PABPC1 (1–636) was expressed
and purified from E. coli using an N terminal His-SUMO
tag. His-SUMO-PABPC1 (1–636) was transformed into
Rosetta2 (DE3) and grown on LB agar, supplemented with
50 g/ml Kanamycin and 33 g/ml Chloramphenicol,
and incubated at 37◦C overnight. Cell culture and induc-
tion were carried out using identical protocols to His-TEV-
LARP1. Purification of PABPC1 was carried out on ice or
at 4◦C unless stated. Cell pellets were resuspended in 10%
(w/v) in Lysis Buffer (as used for LARP1 with the exception
of a higher, 40 mM imidazole concentration). Lysis by soni-
cation was carried out and cell lysates centrifuged at 47 000g
for 1 h, followed by filtration through a 0.2 m filter. Su-
pernatant was loaded onto a 5 ml HisTrap HP column, pre-
equilibrated with Loading Buffer (50 mM Tris–HCl pH 7.5,
500 mM NaCl, 10% (v/v) glycerol, 40 mM imidazole) and
washed first with 10 CV of Loading Buffer and then with
25 CV of High Salt Buffer (50 mM Tris–HCl pH 7.5, 1 M
NaCl, 10% (v/v) glycerol). His-SUMO-PABPC1 was eluted
from the column with 50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 10% (v/v) glycerol, 250 mM imidazole. The eluted
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peak was pooled and incubated overnight with SUMO pro-
tease (Life sensors) at 4◦C using 10 U/1 mg of target pro-
tein. The resulting sample was diluted 1 in 6 with Heparin
A Buffer (50 mM Tris–HCl pH 7.5, 10% (v/v) glycerol, 1
mM DTT). Sample was loaded onto a 5 ml HiTrap Hep-
arin HP column, pre-equilibrated with Heparin Running
buffer (50 mM Tris–HCl pH 7.5, 30 mM NaCl, 10% (v/v)
glycerol, 1 mM DTT) and washed with 30 CV of the same
buffer. PABPC1 was eluted in a linear 30 mM to 1 M NaCl
gradient in Heparin Running Buffer over 20 CV. Fractions
containing PABPC1 were pooled and concentrated to ∼1–
2 ml using a Millipore 30kDa MWCO centrifugal concen-
trator. This sample was loaded onto a HiLoad 16/600 Su-
perdex 200 column, pre-equilibrated with SEC Buffer (50
mM Tris–HCl pH 7.5, 500 mM NaCl, 10% (v/v) glycerol, 1
mM DTT). Following identification by SDS-PAGE analy-
sis, PABPC1-containing fractions were pooled and passed
through a 5 ml HisTrap HP column equilibrated in SEC
Buffer to remove residual uncut SUMO-tagged protein. Re-
covered tag-free protein was pooled, aliquoted, snap frozen
and stored at –80◦C.
Immunoprecipitations with recombinant proteins
To study the PABPC1-LARP1 interaction in vitro, 2.5 M
of recombinant His-LARP1 and PABPC1 were incubated
±2 M Dye680-labelled A20-RNA (IBA life science) for
1.5 h at room temperature in 50 mM Tris–HCl, pH 7.5,
500 mM NaCl, 10% (v/v) glycerol. Per reaction 50 l Dyn-
abeads Protein G (Thermo Fisher Scientific) were washed
three times with NP-buffer (20 mM HEPES, 100 mM
KCl, 0.2 mM EDTA, 1 mM TCEP, 0.1% (v/v) IGEPAL
(Sigma-Aldrich)) and coated with 5 g of 6× Histag (ab-
cam ab18184) or IgG-control (sc-137148) antibody for 30
min in NP-buffer at room temperature. Coated beads were
washed three times in NP-buffer and incubated with protein
samples for 15 min at room temperature. Beads were then
washed three times with NP-buffer, mixed with SDS gel
loading buffer, incubated at 95◦C for 3 min and applied to
denaturing polyacrylamide gel electrophoresis. After elec-
trophoresis, gels were stained with Coomassie and bands
visualized using a Licor Odyssey scanner.
RNase degradation assay
To investigate the activity of RNase I, 1 M Dye680-
labelled A20 RNA (IBA life science) was incubated
with 0.25 mg/ml RNase I in the presence of 8 M
competitor RNA (5′-GAAAAAAUUAAAAAAUUAA
AAAAC-3′, IDT) at room temperature in lysis buffer (20
mM Tris–HCl, pH 7.5, 150 mM NaCl, 15 mM MgCl2, 0.5%
(v/v) IGEPAL, 1 mM EDTA, 1 mM NaF, 1 mM glyc-
erophosphate, 1× protease inhibitors (Roche, EDTA-free)).
Before the addition of RNase I and after 1 and 2.5 h reac-
tion time aliquots were taken and mixed 1:1 with stop so-
lution (0.5× TBE, 10 mM EDTA, 0.1% (w/v) SDS, 85%
(v/v) formamide). Samples were heated for 2 min at 95◦C
and loaded on acryladmide–8M–urea TBE gels. After elec-
trophoresis bands were visualized using a Licor Odyssey
scanner. A dye680-labelled A2 dinucleotide was used as a
size marker.
siRNA transfections and RPS16 5′UTR TOP reporter lu-
ciferase assays
SiRNA transfections were performed using
Lipofectamine® RNAiMAX transfection reagent (Ther-
mofisher Scientific 13778150) diluted in OptiMEM
(GIBCO Cat # 11058) at stated final concentrations. Neg-
ative control siRNA was ON-TARGETplus non-targeting
siRNA #3 (Thermo Scientific, catalogue # D-001810-30).
siRNA against LARP1 (NM 033551.3) was custom or-
dered from Invitrogen (Fwd 5′gugaacccguggacuaagaac 3′
Rev 5′ guucuuaguccacggguucac 3′). HeLa cells were seeded
at a density of 50 000 cells/well on top of the reverse-siRNA
mix. Per well the transfection mix was as follows: 0.6 l
20 nM siRNA plus 3 l RNAiMAX prediluted in 46.4 l
OptiMEM media. Transfection mix (50 l) was pipetted
into each well prior to 550 l of cells, to give a final con-
centration of 20 nM siRNA. Replicate plates were plated
to allow for luciferase assays and RNA extractions from
set 1 and western blots from set 2. Medium was changed
after 24 h and after 48 h cells were transfected with reporter
plasmids using GeneJammer reagent as follows: Per well,
1.8 l of GeneJammer reagent was diluted with 18.2 l
OptiMEM and incubated at room temperature for 5 min.
Then 500 ng per well of RPS16-PEST-CL reporter and
100 ng per well of control pRL-SV40 vector (Promega
catalogue # E2231) used as control vector were added
and transfection mix incubated for 30 min at RT. Then
20 l of transfection mix was added to the relevant wells
and left for 24 h. Medium was replaced with 500 l of
medium containing 200 nM Torin1 or DMSO (control)
and FBS/L-glutamine (as previously described) for 2h.
Medium was aspirated and wells rinsed once with 2 mL
PBS. PBS was then aspirated and 100 l of passive lysis
buffer added per well for luciferase plates and 75 l IP
lysis buffer for western wells. Plates were incubated for 15
min with gentle rocking and then frozen at –80◦C. For
luciferase assays plates were defrosted and 10 l of passive
lysis buffer lysate were assayed in duplicate for each of
three triplicate wells using the Dual-Luciferase Reporter
Assay System (Promega) on a GloMax 96 Microplate
Luminometer (Promega) using Promega protocol with 50
l injections of each reagent. Relative luciferase activity
was calculated as a ratio of firefly luciferase to Renilla
luciferase (with normalization to an internal control to
account for inter-experimental variance). 40 l of the
same lysate was used for RNA extractions and RT-qPCR
analysis was performed using luciferase primers listed in
Supplementary Table S4. For corresponding westerns,
plates were defrosted and 3 × 75 l lysates (triplicate wells)
were pooled and spun at 13 000 rpm 20 min and lysates
normalized for protein concentration following Bradford
assays. Western blots were performed using indicated
antibodies.
Polyadenylation test (PAT)
Polyadenylation assays were performed and analysed
on mRNA purified from HeLa cell lysates treated
with/without mTOR inhibition as described in (68).
Primers used are listed in Supplementary Table S6.
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Statistical analysis
Unless otherwise stated, error bars represent mean ± 1 SD
of the replicates, with numbers of independent experiments
(N) indicated in the figure legends. Statistical testing was
performed using the Student’s t-test, unpaired, two-tailed.
In all cases significance is indicated as follows: *P ≤ 0.05,
**P ≤ 0.01, ***P ≤ 0.001.
RESULTS
Identification of mTOR-regulated RNA-binding proteins
We carried out a time-course to establish the optimal condi-
tions under which both mTORC1 and mTORC2 are inhib-
ited by Torin1 in HeLa cells (Supplementary Figure S1A).
Consistent with dual inhibition of mTORC1 and mTORC2
function, we observed decreased phosphorylation of AKT,
p70S6K, RPS6 and 4E-BP1 (Supplementary Figure S1Ai)
following 1 h exposure to the drug (17,69). eIF4F complex
integrity was assessed by m7GTP-sepharose affinity chro-
matography. The association of eIF4E with eIF4G1 was
markedly decreased after 1 h of drug treatment and was ac-
companied by a concurrent increase in the association of
4E-BP1 with eIF4E (Supplementary Figure S1Aii). North-
ern blot analysis of sucrose density gradients demonstrated
that TOP-containing mRNAs including eEF2, RPS16 and
RPL24 all shifted to the sub-polysomes (non-translating
state) upon mTOR inhibition, as expected (70), with less
of a change in the control -actin transcript, a non-TOP
mRNA (Figure 1A). This confirmed that the experimental
conditions at this 1 h timepoint were optimal for further in-
vestigations.
To identify the RBPs that change their RNA binding ca-
pacity to polyA+ RNA following mTOR inhibition, we per-
formed RNA interactome capture adapted from Castello
et al. (71), as described in materials and methods, 1 h after
exposure to Torin1 (Figure 1B, Supplementary Figure S1B
(72)). Affinity purified RBPs (Supplementary Figure S1C)
were identified and quantified by mass spectrometry and
log fold change was plotted against log adjusted P-value
(Figure 1C). Of the 214 RNA-binding proteins present in
all three replicates (Supplementary Table S1), two proteins
showed increased and 20 decreased binding to RNA fol-
lowing mTOR inhibition (Supplementary Table S2). These
observations were validated by western blot analysis (Fig-
ure 1D); two proteins, HNRNPQ and PSF, which did not
change their RNA binding following mTOR inhibition
were used as positive controls (Figure 1D). Our data show
that LARP1 increased its association to RNA following
mTOR inhibition (Figure 1D). This protein has been im-
plicated in TOP mRNA regulation (38–42,73–77), binding
directly to the m7Gppp-C cap and the adjacent TOP motif
via the DM15 region (39–40,42). Similarly, the E3 ubiqui-
tin ligase TRIM25 (78–80) displayed increased binding fol-
lowing mTOR inhibition (Figure 1D, Supplementary Table
S1). TRIM25 has been shown previously to interact with
non-coding RNAs (81). RBPs that showed decreased RNA
binding included the ribosome associated protein SERBP1
(PAIR-B) (82–84) and PWP2. PWP2 has known roles in
pre-ribosomal RNA processing and ribosomal biogenesis
(85,86) and has been linked to regulation by S6 kinases (87)
(double knockout of S6K1 and S6K2 cause a decrease in
transcript levels of PWP2). A number of ribosomal proteins,
including ribosomal protein RPS10, decreased their bind-
ing to RNA subsequent to mTOR inhibition, indicative
of translational repression (88). Whilst mTOR inhibition
would also be consistent with certain eIF4F complex com-
ponents including eIF4G decreasing in association (Supple-
mentary Figure S1A), within the RNA interactome capture
data we observed eIF4G showing a decrease in binding fol-
lowing mTOR inhibition, however this failed to reach sig-
nificance (Supplementary Table S1).
To identify the RNAs bound by TRIM25 and LARP1
(increased RNA binding), and SERBP1 and PWP2 (de-
creased RNA binding), flag-tagged versions of each of these
four proteins were transiently overexpressed in HeLa cells.
RNA-immunoprecipitation (RIP) was performed (Sup-
plementary Figure S2A) and the associated RNAs were
extracted and analysed on gene expression microarrays.
LARP1 showed enrichment of the greatest number of
mRNAs, 2546 (Supplementary Figure S2B), followed by
SERBP1 with 1261 mRNAs, whereas TRIM25 and PWP2
showed no significant mRNA enrichment consistent with
their previously published roles in non-coding and ribo-
somal RNA interactions. A significant number of TOP
mRNAs that encode ribosomal proteins were among the
LARP1-enriched mRNAs (Supplementary Figure S2C).
Only a subset of LARP1-bound mRNAs are dependent on
mTOR
To determine the effect of mTOR inhibition on LARP1-
dependent mRNA binding, we performed RNA-IPs (RIP)
of endogenous LARP1 from HeLa cells ± mTOR inhibi-
tion (Figure 2A). Microarray analysis of the associated mR-
NAs showed a large set of 2566 transcripts were bound by
LARP1 in both conditions, henceforth referred to as con-
stitutively bound, as well as 656 mRNAs with significantly
increased binding following mTOR inhibition, henceforth
referred to as having induced binding (Figure 2B and Sup-
plementary Table S3). mRNAs with induced LARP1 bind-
ing after mTOR inhibition include the GO functional an-
notations for translation and response to nutrients (Figure
2C). The microarray results were validated by RT-qPCR
(Figure 2D) and confirmed to be maintained and specific,
not a result of post-lysis interactions (89) by performing UV
cross-linking prior to RIP (Supplementary Figure S3). We
confirmed that RNAs including histones such as Histone
2H2AC and non-coding RNAs such as RN7SK are not en-
riched in the LARP1 IP (Figure 2D); histone mRNAs are
not regulated by mTOR (31) and, in general, do not have
poly(A) tails (reviewed in (90)). Importantly, changes in
RNA binding were not accompanied by significant changes
in RNA levels following mTOR inhibition (Supplementary
Figure S4). Detailed transcript analysis at the nucleoside-
level reveals that the set of mRNAs bound by LARP1
(mTOR inhibition induced and constitutively bound mR-
NAs) have high GC content in both their coding sequence
and 5′UTR (Figure 2E). Interestingly, within the coding re-
gion it is specifically the GC content at the third or ‘wobble’
position of codons that most differentiates LARP1 bound
mRNAs (Supplementary Figure S5).
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Figure 1. Changes in RNA-binding proteins upon mTOR inactivation. (A–D) HeLa cells were treated with 200 nM Torin1 or DMSO as control. (A)
Polysome profiling was performed and RNA from fractions was analysed by Northern blot. Representative UV traces from one of two independent
experiments and corresponding blots from gradient fractions using probes against indicated RNAs are shown. B–D: Whole cell RNA-binding protein
(RBP) capture using oligo(dT) affinity isolation. (B) Representative western blots of lysates from one of three experiments used for oligo(dT) pulldowns
in C and D to show mTOR inactivation and equal loading using indicated antisera. Asterisks denote p85S6K. (C) Plot of mean fold change of proteins
identified in control (DMSO carrier) versus Torin1 (mTOR inhibited) RBP capture (using TOP3 unique peptides for quantitation). Cut-offs shown on graph
are log FC > 1.3, adjusted P-values <0.2 using Benjamini–Hochberg adjusted P-value. Following Torin1 treatment: gold = RBP decreasing binding; cyan
= RBP increasing binding; black = no significant change in binding. Three independent experiments performed. (D) Validation of changes in RNA-binding
proteins upon mTOR inactivation. Representative western blots of proteins changing their RNA binding following mTOR inhibition from independent
oligo(dT) pulldowns n = 5.
LARP1 represses translation of TOP mRNAs downstream of
mTOR
As mentioned earlier, the mRNAs with increased associa-
tion with LARP1 following mTOR inhibition include GO
terms relating to translation and response to nutrients (Fig-
ure 2C). Consistent with this and in agreement with earlier
studies including LARP1-CLIP experiments (38–40,73), we
find enrichment of TOP mRNAs with LARP1 after mTOR
inhibition (Figure 3A and B). We did not find a large over-
lap between our LARP1 RIP data and the CLIP data from
Hong et al (73), possibly due to the distinct methodologies
and biological systems employed. To further understand
the role of LARP1 on the expression of TOP mRNAs, lu-
ciferase reporter constructs containing the promoter and
5′UTR of RPS16 upstream of firefly luciferase were used
(further vector details in materials and methods). A vector
containing five mutations within the first six bases of the
TOP motif (CCUUUUCC mutated to GAGUGACC) was
employed as a mutated-TOP negative control (Figure 3C, D
and Supplementary Figure S6). Luciferase activity was ex-
amined in control and LARP1 knockdown conditions +/-
Torin1 treatment ((Figure 3D and Supplementary Figure
S6). We observed that, in the presence of LARP1, the WT
RPS16 5′UTR-containing reporter, but not the mutant, was
susceptible to mTOR inhibition and that this is dependent
on LARP1, as its depletion abrogated the reporter’s sensi-
tivity to mTOR inhibition ((Figure 3C, D, Supplementary
Figure S6).
Translational control of LARP1 bound mRNAs
To probe the relationship between LARP1 binding and
translation on endogenous mRNAs, HeLa cells ± Torin1
treatment were subjected to sucrose gradient analysis (Fig-
ure 4A). The distribution of several LARP1-bound mR-





Figure 2. mRNAs associated with LARP1 with and without mTOR inactivation. HeLa cells were serum stimulated followed by control or Torin1 treat-
ment. Endogenous LARP1 immunoprecipitation was performed and beads split for analysis of RNA and proteins. (A–C) mRNA arrays were performed
using RNA extracted from both input and LARP1 pulldowns in control and mTOR inhibited conditions. The experiment was performed four times in-
dependently. (A) Western blots of endogenous LARP1 immunoprecipitates and 10% input samples from one representative experiment using indicated
antibodies. (B) Number of RNAs significantly enriched over input in LARP1 IPs (Control log FC > 0.5 & Torin1 log FC > 0.5). (C) Genes uniquely
assigned to either the induced or constitutively bound groups were assessed for enrichment of gene ontology biological process (BP) terms using David
functional annotation. The graphs present terms enriched with an FDR < 0.05. (D) qPCR validation of RNA enrichment over input using primers for
indicated RNAs, expressed as mean relative enrichment in LARP1 pulldown over input. mRNAs defined as unbound, constitutively bound or induced
bound to LARP1 as described in main text. Paired 2-tailed t test on the means of three independent experiments. (E) Analysis of the GC content of
5′UTR and CDS sequences of all RefSeq mRNAs and LARP1 bound mRNAs. The term constitutively depleted refers to mRNAs that are significantly
depleted (LogFC > –0.5) in both control and mTOR inhibited conditions and ‘induced depleted’ refers to mRNAs that are unbound in control conditions
(FDR > 0.05) and depleted (log FC < –0.5) in Torin1-treated conditions. Medians indicated by black lines and statistical significance calculated using
Kruskal-Wallis followed by Dunn test.
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Figure 3. LARP1 binding to terminal oligopyrimidine tract containing mRNAs increases after mTOR inactivation. Log fold enrichment over input of all
LARP1 bound mRNAs following immunoprecipitation from (A) Control treated or (B) Torin1 treated HeLa cells. mRNAs significantly (FDR < 0.05)
enriched (LARP1 bound) or depleted over input shown in red, of these, blue data points represent TOP containing mRNAs as listed in (5). Non-significantly
enriched mRNAs are in grey. C and D: HeLa cells transfected at a final concentration of 20 nM control or LARP1 siRNA were subsequently transfected
with RPS16- PEST-CL reporters and control pRL-SV40 vector (Promega E2231). After 24 h, cells were treated with Torin1 or DMSO (control) for 2h
followed by lysis. Experiment performed three times. (C) Western blots were performed using indicated antibodies. Representative western blots shown
from one experiment of three. (D) Luciferase assays were performed in duplicate for each of 3 triplicate wells. Relative luciferase activity was calculated
as a ratio of firefly luciferase to renilla luciferase. These were then normalized to firefly RNA levels to determine luciferase protein expression changes.
The means and individual data points of three independent experiments are plotted with error bars indicating SD. Non-RNA normalized data is shown
in Supplementary Figure S6.
NAs across the polysome gradients was measured by RT-
qPCR (Figure 4A). mRNAs that showed increased bind-
ing to LARP1 following mTOR inhibition, including eEF2
and LDHA, relocated from a ‘heavy’ polysomal distribu-
tion (containing many ribosomes) to a ‘light’ (contain-
ing 2–4 ribosomes) or sub-polysomal distribution (Figure
4A and Supplementary Figure S7A), indicative of trans-
lational inhibition. Interestingly, the constitutively-bound
mRNAs displayed a distinct distribution across the gra-
dients. Firstly, they appear to be loaded with fewer ribo-
somes and secondly, show no net change in polysome as-
sociation following mTOR inhibition (Figure 4A, B and
Supplementary Figure S7A). To assess if these mRNAs
were translationally stalled/silenced, cells were treated with
puromycin to dissociate actively elongating ribosomes. The
data show that the distribution of mRNAs with induced
binding to LARP1 following mTOR inhibition relocated to
lighter fractions of the gradient following puromycin treat-
ment. However, mRNAs that bind to LARP1 irrespective
of mTOR inhibition, do not shift to lighter polysomes after
puromycin treatment (Figure 4C, right hand panel and Sup-
plementary Figure S7B). The puromycin insensitivity sug-
gests that the majority of these mRNAs are not actively en-
gaged with translocating ribosomes, but they are presum-
ably associated with as yet undefined RNP complexes (91).
To further examine if the LARP1-associated mRNAs are
globally translationally repressed and whether repression
is dependent upon LARP1, a pre-existing ribosome profil-
ing dataset from Philippe et al (43) was interrogated. This
study included ribosome profiling in HEK293 cell lines with
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Figure 4. Polysome distribution of LARP1 bound mRNAs. HeLa cells supplemented with serum and then 200 nM Torin1 or DMSO vehicle control. (A-C)
Sucrose density gradients were run and RNAs extracted from individual fractions. (A) Top panel: UV 254 traces of polysome gradients from control and
Torin1 treated HeLa cell extracts. Lower panels: Percentage mRNA distribution across polysome gradients calculated from RT-qPCR. Data presented from
one experiment representative of three independent experiments. (B) Western blots of input samples from A, for one of three independent experiments using
indicated antibodies. (C) HeLa cells were treated with 200 g/ml Puromycin for 1 h or 100 g/ml cycloheximide for 3 min (Control). Sucrose gradients as
in A. RNA was extracted from individual fractions and qPCR performed. Top panel: UV 254 traces of polysome gradients from control and puromycin
treated HeLa cell extracts. Lower panels: Representative percentage mRNA distribution across polysome gradients calculated from RT-qPCR. (D) LARP1
constitutively bound mRNAs show reduced ribosome occupancy across the CDS. Graph shows RPF coverage normalized for mRNA abundance against
normalized CDS length.





Figure 5. mRNAs associated with endogenous PABPC1 with/without mTOR inactivation and overlap with LARP1. (A–D) PABPC1 and control IgG
immunoprecipitation from HeLa cells following mTOR inactivation. (A) Representative western blots of PABPC1 IP and input samples using indicated
antibodies. (B) RNAs significantly enriched over input (log FC > 0.5) in PABPC1 IPs. Analysis performed as in Figure 2. (C) Genes uniquely assigned to
either the induced following mTOR inhibition or constitutive group for PABPC1 were assessed for enrichment of gene ontology biological process (BP)
terms using David functional annotation. The graphs present terms enriched with an FDR < 0.05. (D) QPCR validation of RNA binding to PABPC1
following mTOR inhibition. (E) Overlap of RNA enrichment over input in PABPC1 and LARP1 IPs from either control or Torin1 (mTOR inhibited)
conditions. Pink and blue dots represent statistically significant enriched mRNAs in overlapped IPs from control or Torin1 conditions, respectively. Gray
dots are non-significantly enriched mRNAs. R2 values displayed. (F) mRNAs bound by LARP1 or LARP1 & PABPC1 display decreased ribosome
occupancy throughout the CDS. Groups used for this figure are listed in Supplementary Table S7.
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and without LARP1, ± Torin1 treatment. We examined
the groups of mRNAs that were either unbound, constitu-
tively or induced bound following mTOR inhibition. Den-
sity plots of translational efficiency (TE) for these groups
is shown (Supplementary Figure S8) for HEK293 cells with
LARP1 knockout (KO) (dark and light blue) in comparison
to the control wild type (WT) cell line (dark and light green).
The mean translational efficiency (⁞) of both LARP1 consti-
tutively bound mRNAs and LARP1 mTOR inhibition in-
duced bound mRNAs increases in the absence of LARP1.
Whereas mRNAs that are not bound to LARP1 show no
change in translational efficiency in the presence or absence
of LARP1 (bottom panel). This indicates that LARP1 re-
presses the translation of associated mRNAs. In addition,
this data also shows that mRNAs bound by LARP1 fol-
lowing mTOR inhibition (LARP1 induced bound mRNAs)
show a decrease in TE following Torin1 treatment in control
cells (middle panel, dark green compared to light green) and
this is slightly reduced in the knockout cells (dark blue com-
pared to light blue). However, the TE of the constitutively
bound mRNAs is not majorly affected by mTOR inhibi-
tion (top panel). Importantly, a metagene analysis showed
that the mean ribosome occupancy across transcript open
reading frames for LARP1 constitutively bound mRNAs
is lower than unbound mRNAs (Figure 4D). Altogether,
these data suggest that LARP1 binding correlates with re-
duced ribosomal occupancy––i.e. LARP1 likely represses
the translation of mTOR-sensitive and importantly insen-
sitive mRNAs.
PABPC1-bound RNA changes following mTOR inhibition
overlap strongly with LARP1
LARP1 has been previously shown to interact with
PABPC1 directly (38,92), and it was therefore important to
assess how PABP influences the binding of LARP1 to spe-
cific mRNAs, particularly as PABPC1 has been shown pre-
viously to activate translation (93,94). Endogenous LARP1
pulldowns in the presence of RNase I confirmed an RNA-
independent interaction with PABPC1, which is unaffected
by mTOR inhibition (Supplementary Figure S9A–C). We
also tested whether bacterially expressed LARP1 could in-
teract with PABPC1 and found that these two proteins
did interact (Supplementary Figure S9D) and the amount
of PABPC1 co-precipitating in His-LARP1 pulldowns in-
creased with the addition of Dye680-labelled A20 RNA.
This suggests that the interaction of LARP1 and PABPC1
may be strengthened by the association with RNA.
We hypothesized that the PABPC1-LARP1 interaction
may be involved in the differential sensitivity of LARP1-
bound mRNAs to mTOR. To examine the role of PABPC1
in this regard, PABPC1 RNA-IP was carried out ±mTOR
inhibition and the mRNAs analysed by cDNA microarray
(Figure 5A), an experiment complementary to the LARP1
RIP (Figure 2). The data show (Figure 5B and Supplemen-
tary Table S3) PABPC1 bound to 3700 mRNAs, a large
number, which was unsurprising given its role in mRNA
translation (93,94). Gene ontology enrichment analysis
showed that upon mTOR inhibition there was an enrich-
ment of mRNAs encoding proteins related to translation
and mitochondrial translational elongation/termination
(Figure 5C). RT-qPCR validation showed that the mR-
NAs bound by PABPC1 have a similar profile to that of
LARP1, with two distinct groups of mRNAs identified:
those constitutively bound by PABPC1 and those where
mTOR inhibition increased mRNAs binding (Figure 5D).
We then examined the degree of overlap of mRNAs bound
to both LARP1 and PABPC1 in untreated cells or fol-
lowing mTOR inhibition (Figure 5E). The data show that
there is a strong positive correlation in enrichment of mR-
NAs recovered in the LARP1/PABPC1 immunoprecipi-
tations in both the control and Torin1 treated cells. The
extent of the overlap was somewhat surprising given that
PABPC1 has a well-described function as a positive reg-
ulator of translation. Indeed, examining ribosome profil-
ing data for the ribosome occupancy across the coding
sequences of groups of mRNAs bound by LARP1 and
PABPC1, we observe that the mean ribosome occupancy
of LARP1 and LARP1/PABPC1 bound mRNAs is lower
than of those bound to PABPC1 alone (presumably when
associated with the eIF4F complex), supporting a role of
PABPC1 as an activator of translation when independent
of LARP1 (Figure 5F, RNA groupings are defined in Sup-
plementary Table S7). The PABPC1 bound mRNAs (or-
ange) show lower mean ribosome occupancy than depleted
mRNAs (gray), which would indicate that they are trans-
lated less than the unbound mRNAs. There are several rea-
sons why this may be the case. One is that many of the
unbound mRNAs are non-canonical (non polyadenylated
for example) transcripts such as histones and may gener-
ally be highly expressed and be regulated in a different man-
ner from PABPC1 bound mRNAs. Secondly, PABPC1 as-
sociates with other regulatory proteins other than eIF4G,
for example PAIP1 or PAIP2 and this may result in re-
ducing the TE of this group. However, importantly, it ap-
pears to be the minority of mRNAs (264) that are bound
to PABPC1 only, while the majority, 1010 mRNAs are
PABPC1-LARP1 bound.
When we look at the translational efficiency of PABPC1–
LARP1 bound mRNAs using TE data from Philippe et al.
(43) (Supplementary Figure S10), mRNAs bound by both
LARP1 and PABPC1 show increased TE in LARP1 knock-
out cells (dark and light green) compared to the same
treatments in the control cell line (dark and light blue).
LARP1 only bound mRNAs also have increased transla-
tional efficiency in LARP1 knockout cells. The TE of un-
bound mRNAs (third panel) show no difference between
LARP1 knockout cells and controls. PABPC1 bound mR-
NAs show decreased TE following Torin1 treatment in
control cells (bottom panel, dark green compared to light
green) and this is slightly reduced in the knockout cells (light
blue compared to dark blue). PABPC1 only bound mR-
NAs also show increased translational efficiency in LARP1
knockout cells, this could in part be due to some of these
mRNAs being bound and controlled in some instances
by LARP1 at lower levels than our threshold cut-off for
binding/enrichment. Overall, this data shows that LARP1–
PABPC1 bound mRNAs are translated less efficiently than
mRNAs bound to PABPC1 only or unbound mRNAs.
The extent of PABPC1 binding to mRNA is strongly in-
fluenced by poly (A) tail length (95). However, poly(A)-
tail length (PAT) assays showed that there were no gross
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changes in the poly(A) tail length of mRNAs from LARP1
bound or unbound groups during this time window of
Torin1 treatment (Supplementary Figure S11).
Preventing LARP1/PABPC1 interaction severely disrupts
LARP1 mRNA interaction
LARP1 possesses several RNA binding motifs, including
within the La module which has been reported to bind
poly(A) and pyrimidine rich mRNA (77); a conserved La
motif (LAM) and the RRM5-like RNA binding domain.
The La module additionally contains a PAM2 (PABPC1-
binding) domain (38,96) (Figure 6A). There is scope for the
LAM and RRM-L5 to act synergistically with regards to
substrate binding as found in other La protein family mem-
bers (97), however for LARP1 this has not been fully in-
vestigated. Mutation of the PAM2 domain has been pre-
viously shown to reduce PABP binding (38). The DM15
region (comprised of three DM15 modules) is unique to
LARP1/LARP1B and lies towards the C-terminus of the
protein (40).
Given that our data suggest that LARP1 and PABPC1
bind similarly to mRNAs that do or do not change their
interaction following mTOR inhibition, we investigated the
relative contributions of the PAM2 and DM15 domains to
these interactions.
To assess the relative impact of LARP1′s interaction
with both PABPC1 via the PAM2 domain or directly with
mRNA via the DM15 domain, mutations were introduced
into these domains of LARP1. Flag-tagged version of
LARP1 wild type (WT) and versions containing point mu-
tations in two conserved residues of the PAM2 domain
(L423A/F428A, Figure 6A (38)) or two residues in the
DM15 domain of LARP1 (R840 and Y883), which have
been shown previously to be required for TOP mRNA bind-
ing and cap structure recognition, respectively (39,40) were
overexpressed. Flag affinity purifications of LARP1 wild
type (WT) and mutants were performed (Figure 6B) and
associated RNAs were extracted, with flag-bacterial alka-
line phosphatase (BAP) used as a negative control. As ex-
pected, the mutations in the PAM2 domain resulted in a
decreased PABPC1–LARP1 interaction, but unexpectedly
this correlated with a significant decrease in overall RNA
binding (Figure 6Ci, ii and Supplementary Figure S12A). A
similar decrease was also observed when using Flag-tagged
N-terminal LARP1 containing the PAM2 L423A/F428A
mutations (Figure 6D and E). Interestingly, in the context
of full length LARP1, the DM15 R840E/Y883A muta-
tions did not cause any significant decrease in the capac-
ity of LARP1 to bind RNA, including the TOP-containing
mRNAs, eEF2, RPL13, RPL28 and HNRNPA1 (Figure
6Ci and ii), nor did they have an effect on PABPC1 bind-
ing (Figure 6B). The sustained mRNA binding may in
part be due to the La module mRNA binding (77). We
however confirm that the C-terminal 615–1019 section of
LARP1 (Supplementary Figure S13A–C) shows enhanced
binding to LARP1 target mRNAs in comparison to BAP
control and that these interactions are perturbed by the
R840E/Y883A mutations (Supplementary Figure S13C).
While this demonstrated the importance of these residues
for DM15-mRNA interactions, the C-terminal portion of
LARP1 did not confer the mRNA binding specificity ob-
served with wildtype protein, with histone 2H2AC mRNA
now interacting (Supplementary Figure S13C, Figure 6C).
This could mean that either PABPC1 or other RNA binding
domains in LARP1′s N-terminus direct LARP1 to specific
mRNAs. The role of the PAM2 domain and the interaction
with PABPC1 was also highlighted by the observation that
the LARP1 L423A/F428A mutant did not associate with
polysomes in comparison to wild type LARP1 (Supplemen-
tary Figure S14).
The LARP1 La module has previously been shown to
bind both poly(A) and CU rich mRNA by Al-Ashtal et al.
(77). To address the question whether PABPC1 is required
for the delivery of these mRNAs to LARP1 using a distinct
experimental approach, we over-expressed the PABPC1
binding protein PAIP2, which interacts with the MLLE do-
main of PABPC1 via its PAM2 domain (Figure 6F). As ex-
pected, this resulted in the sequestration of PABPC1, pre-
vented its interaction with LARP1 (Figure 6F) and this re-
sulted in a decrease of RNA association with LARP1 of
a panel of mRNAs (Figure 6G and Supplementary Figure
S12B). These data suggest that PABPC1 directs or induces
a conformational change in LARP1 required for increased
RNA binding. Our findings also provide further rationale
for the specificity of LARP1 to poly(A) tail-containing
mRNAs supported by the data which show that histone
mRNAs, which lack poly(A) tails (98), are not bound by
LARP1.
DISCUSSION
RNA-binding protein capture was used to identify the
changes in the RNA protein interaction network following
mTOR inhibition (Figure 1 and Supplementary Tables S1
and S2). In total, we identified 22 proteins that change their
association with RNA following mTOR inhibition, two of
which, LARP1 and TRIM25, increased their binding to
mRNA. LARP1 has been implicated in the regulation of
TOP mRNAs downstream of mTOR (38–41,73,75,77) and
our data confirm this. This activity may be context depen-
dent since other data demonstrate that insulin (a stimulator
of mTOR signalling, reviewed in (99)) increases the bind-
ing of LARP1 to TOP-containing mRNAs (41). Here, we
find that endogenous LARP1 associates with TOP mRNAs,
in addition to a large subset of other mRNAs (Figures 2
and 3), and that this binding correlates with their transla-
tional repression. The E3 ubiquitin ligase TRIM25 was also
identified as increasing its RNA binding following mTOR
inhibition. TRIM25′s ubiquitin ligase activity has been re-
ported to be stimulated by RNA binding (81). The 20 pro-
teins which reduced their interaction with mRNA follow-
ing mTOR inhibition (Figure 1C and Supplementary Table
S2), included ribosomal proteins and associated factors, e.g.
SERBP1 (82–84) and these are currently under further in-
vestigation.
We identified nearly 4000 mRNAs that are enriched in
LARP1 immunoprecipitates (Figure 2B), and these formed
two distinct groups, i.e. mRNAs that change their asso-
ciation with LARP1 following mTOR inhibition (referred
to as ‘induced’) and those bound to LARP1 under both
conditions (‘constitutively’ bound). Importantly, our data
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Figure 6. Dissecting the functional domains of LARP1. (A) Schematic representation of the LARP1 constructs used in overexpression experiments. Amino
acid numbering based on LARP1 Isoform 2 (Q6PKG0–3) B-C. Immunoprecipitation of transiently overexpressed Flag-tagged LARP1 2–1019: wild type
(WT); PAM2 L423A/F428A double point mutant (PAM); DM15 R840E/Y883A double point mutant (DM) or flag tagged bacterial alkaline phosphatase
(BAP) control protein from HeLa cells treated with or without Torin1. (B) Western blots of Flag tagged protein overexpression in 10% inputs and immuno-
precipitations from one representative experiment of three. (C) (i) and (ii). Mean relative enrichment from qPCR analysis as mean relative enrichment in
Flag pulldowns over input with data points from three individual experiments plotted. D-E. HeLa cells were transiently transfected with either: Flag
tagged wild type LARP1 N-terminus (‘WT LARP1 Nt’ -amino acids 2–598) wild type (WT); LARP1 N-terminus PAM2 L423A/F428A double point
mutant (PAM) or bacterial alkaline phosphatase (BAP) flag tagged control protein. Cells were treated plus or minus mTOR inhibition using Torin1 and
flag immunoprecipitations performed. (D) Western blots of Flag tagged LARP1 N-terminal (Nt) (2–598) truncation overexpression in 10% inputs and im-
munoprecipitations using indicated antisera. Blots are from one representative experiment, N = 3. (E) Mean relative enrichment from qPCR as in C. (F and
G) HeLa cells were transiently transfected with empty vector or PAIP2 and left for 24h. Endogenous LARP1 immunoprecipitations were then performed
from control or 200 nM Torin1 treated cells. (F) Westerns blots showing mTOR inhibition and overexpression of PAIP2 and the resulting reduced capacity
of PABPC1 to bind to LARP1 using indicated antibodies. Western blots from one representative experiment, N = 3. (G) qPCR enrichment analysis of
LARP1 bound mRNAs in the absence and presence of PAIP2 overexpression as in (C).
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confirmed that LARP1 can interact directly with PABPC1
(Supplementary Figure S9) and examination of the mR-
NAs that associated with both LARP1 and PABPC1 sug-
gested that they are co-ordinately regulated by these pro-
teins following mTOR inhibition (Figure 5E). Recent work
on LARP1 has highlighted that LARP1 plays a role in the
regulation of mRNAs important for mitochondrial func-
tion (100) and work by Zhang has shown that Drosophila
LARP shows some mitochondrial outer membrane local-
ization (101) where it controls the translation of cytoplas-
mic mRNAs important for mitochondrial function. Addi-
tionally, studies have now shown that PINK1 phosphoryla-
tion of LARP represses local translation at the mitochon-
drial surface (102). Indeed we see mitochondrial related GO
terms in both the LARP1 and PABPC1 RIP analysis, espe-
cially with PABPC1 following mTOR inhibition (Figures
2C and 5C respectively). The bottom two panels of Sup-
plementary Figure S7A show polysome distribution of two
nuclear-derived mRNAs that encode mitochondrial pro-
teins that exhibited increased binding after mTOR inhibi-
tion to both PABPC1 and LARP1 (mRNAs encoding the
mitochondrial acyl carrier protein NDUFB5 and FARS2,
a mitochondrial tRNA ligase). We find that these two mR-
NAs come out of the polysomes following mTOR inhibition
(Supplementary Figure S7A) suggesting decreased transla-
tion upon mTOR inhibition.
We show that the PAM2 domain of LARP1 is required
for its interaction with PABPC1 (Figure 6) and importantly
that mutation of the PAM2 domain or overexpression of
PAIP2, which sequesters PABPC1 away from LARP1, re-
sult not only in the loss of PABPC1 association, but also
results in a large reduction in specific mRNA binding (Fig-
ure 6). Overall, our data suggest that mRNA specificity is
driven by the LARP1-PABPC1 interaction (Figure 6 and
Supplementary Figure S13C) and that in the context of the
full length protein the DM15 region of LARP1 does not
impact on its interaction with PABPC1 and associated mR-
NAs (Figure 5B-C). While the mutations in the DM15 do-
main do not result in loss of mRNA association it would be
expected that lack of cap-binding may prevent mRNA cir-
cularization (Supplementary Figure S15). Multivalent in-
teractions (interactions involving several interaction points)
can influence and produce cooperative and sensitive bind-
ing dynamics and thus enhance the specificity and or func-
tional affinity. The association of PABPC1 and LARP1 to
each other (Supplemental Figure S9) and to the same RNA
cohorts (Figure 5E) along with the data that disruption of
this interaction (Figure 6F and G) reduces RNA binding
suggest that multivalency may well be playing a role in the
dynamics of LARP1-PABPC1-RNA interaction.
The translational efficiency of LARP1-bound mRNAs
is lower than RNAs not enriched on LARP1 (Figure 4D,
Supplementary Figure S8). Importantly, mRNAs bound
by PABPC1, but not LARP1, have higher translational ef-
ficiency than LARP1- and LARP1/PABPC1-bound mR-
NAs (Figure 5F). These results indicate that a subset of
mRNAs bound by PABPC1 but LARP1-independent are
highly translated, presumably eIF4F-associated. Given that
LARP1 can outcompete eIF4E for binding to C-capped
mRNA and that LARP1 binds to PABPC1, we hypothesize
that the LARP1/PABPC1 interaction allows for an eIF4E-
independent closed loop conformation on mRNAs with in-
duced binding following mTOR inhibition (Supplementary
Figure S15).
It is not clear how the mRNAs that are constitutively
bound by LARP1 and PABPC1 are translationally re-
pressed by these proteins, or whether this inhibition is reg-
ulated downstream of different signalling events or stimuli.
One possibility is that when LARP1 and PABPC1 bind to
a single transcript, the mRNA, in addition to being trans-
lationally repressed is also stabilized via protection from
deadenylation by PABPC1 and de-capping by LARP1 via
binding to the 5′ end of the transcript through the DM15
domain.
Taken together, our findings suggest that LARP1 is a neg-
ative regulator of translation through its interaction with
PABPC1 and this interaction is key for targeting LARP1
to specific mRNA. Perturbation of this interaction disrupts
LARP1 mRNA binding. While our data in this context con-
firms LARP1 to be a translational repressor, we cannot ex-
clude that its activity is context dependent.
DATA AVAILABILITY
The mass spectrometry proteomics data has been
deposited to the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org) via the
PRIDE partner repository (103) with the dataset identifier
PXD016705 and DOI 10.6019/PXD016705.
Array data discussed in this publication has been de-
posited in NCBI’s Gene Expression Omnibus (104) and




Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We would like to thank Professor Simon Morley for the pro-
vision of copious amounts of PABPC1 antisera. We would
also like to thank Gaia Di Timoteo for her time as an Eras-
mus student working on aspects of this project that were
in the end not included in the manuscript. We would also
like to thank Anders Lund for the gift of the RPS16 TOP
reporter constructs that we used after extensive modifica-
tion and Paul Garside for his work in modifying these con-
structs.
Author contributions: E.M.S. performed mTOR inhibi-
tion time courses, oligo(dT) optimizations, RNA interac-
tome capture and validations, sucrose gradients and north-
ern blots, generated overexpression constructs, performed
endogenous immunoprecipitations, Flag immunoprecipi-
tations, qPCR validations and western blotting. NEHB
performed PABPC1 pulldowns and mRNA analysis and
LARP1 immunoprecipitation mRNA analysis, LARP1
mutant pulldowns and puromycin gradients and RNA anal-
ysis. K.M. performed some mTOR inhibition time course
replicates, and jointly optimized oligo(dT) pulldowns, val-
idations and carried out mass spectrometry analysis. A.W.
476 Nucleic Acids Research, 2021, Vol. 49, No. 1
analysed all of the datasets for gene expression arrays, car-
ried out TE analysis, as well as helping with the process-
ing and analysis of mass spectrometry datasets, G.C. con-
tent analysis and contributed significantly throughout with
constructive discussion. S.G. performed and analysed ribo-
some profiling, as well as helping extensively with bioin-
formatics and analysis. K.C. and R.J.-J. helped design the
mass spectrometry approach for oligo(dT) pulldowns, R.J.-
J. processed samples for mass spectrometry–gel extraction,
trypsinization, reduction/alkylation and performed mass
spectrometry. C.J. performed mRNA arrays and M.S. modi-
fied the protocol for and trained E.S./K.M. in the execution
of the whole cell RNA-binding protein capture method-
ology. T.S. performed RNase I assays and bacterially ex-
pressed His-LARP1 pulldown interaction studies, as well
as the cloning of PABPC1 into His-SUMO expression vec-
tor. H.A.M. designed reagents for and performed PAT as-
says and analysis of these. J.A.W. carried out structure-
seq analysis on LARP1 bound mRNAs. C.B. expressed
and purified bacterially expressed recombinant LARP1 and
PABPC1. B.D.F. provided information on key residues of
LARP1 to mutate from within his experiments and assisted
in troubleshooting various aspects of the polysome exper-
iments. A.E.W. and M.B. co-wrote initial grants for these
experiments and supervised the work performed within this
manuscript. S.B. helped procure funding for N.B. and E.S.
E.S., A.W. and M.B. wrote the manuscript and all authors
were also involved in the proof reading and modification of
the manuscript.
FUNDING
Biotechnology and Biological Sciences Research Coun-
cil [BB/H024980/1 to A.E.W.]; Medical Research Coun-
cil [MC UP A600 1024 to M.B.]; Cancer Research UK
[A29252, A31287]; Cancer Research UK SMERP award
[A22598 to S.B., N.B.]; K.M. was funded through the Med-
ical Research Council [1243972]. Funding for open access
charge: Cancer Research UK [A31287].
Conflict of interest statement. None declared.
REFERENCES
1. Loewith,R., Jacinto,E., Wullschleger,S., Lorberg,A., Crespo,J.L.,
Bonenfant,D., Oppliger,W., Jenoe,P. and Hall,M.N. (2002) Two
TOR complexes, only one of which is rapamycin sensitive, have
distinct roles in cell growth control. Mol. Cell, 10, 457–468.
2. Kim,D.H., Sarbassov,D.D., Ali,S.M., Latek,R.R., Guntur,K.V.,
Erdjument-Bromage,H., Tempst,P. and Sabatini,D.M. (2003)
GbetaL, a positive regulator of the rapamycin-sensitive pathway
required for the nutrient-sensitive interaction between raptor and
mTOR. Mol. Cell, 11, 895–904.
3. Peterson,T.R., Laplante,M., Thoreen,C.C., Sancak,Y., Kang,S.A.,
Kuehl,W.M., Gray,N.S. and Sabatini,D.M. (2009) DEPTOR is an
mTOR inhibitor frequently overexpressed in multiple myeloma cells
and required for their survival. Cell, 137, 873–886.
4. Sarbassov,D.D., Ali,S.M., Kim,D.H., Guertin,D.A., Latek,R.R.,
Erdjument-Bromage,H., Tempst,P. and Sabatini,D.M. (2004) Rictor,
a novel binding partner of mTOR, defines a rapamycin-insensitive
and raptor-independent pathway that regulates the cytoskeleton.
Curr. Biol., 14, 1296–1302.
5. Frias,M.A., Thoreen,C.C., Jaffe,J.D., Schroder,W., Sculley,T.,
Carr,S.A. and Sabatini,D.M. (2006) mSin1 is necessary for
Akt/PKB phosphorylation, and its isoforms define three distinct
mTORC2s. Curr. Biol., 16, 1865–1870.
6. Jacinto,E., Facchinetti,V., Liu,D., Soto,N., Wei,S., Jung,S.Y.,
Huang,Q., Qin,J. and Su,B. (2006) SIN1/MIP1 maintains
rictor-mTOR complex integrity and regulates Akt phosphorylation
and substrate specificity. Cell, 127, 125–137.
7. Woo,S.Y., Kim,D.H., Jun,C.B., Kim,Y.M., Haar,E.V., Lee,S.I.,
Hegg,J.W., Bandhakavi,S., Griffin,T.J. and Kim,D.H. (2007) PRR5,
a novel component of mTOR complex 2, regulates platelet-derived
growth factor receptor beta expression and signaling. J. Biol. Chem.,
282, 25604–25612.
8. Pearce,L.R., Huang,X., Boudeau,J., Pawlowski,R., Wullschleger,S.,
Deak,M., Ibrahim,A.F., Gourlay,R., Magnuson,M.A. and
Alessi,D.R. (2007) Identification of Protor as a novel Rictor-binding
component of mTOR complex-2. Biochem. J., 405, 513–522.
9. Ben-Sahra,I. and Manning,B.D. (2017) mTORC1 signaling and the
metabolic control of cell growth. Curr. Opin. Cell Biol., 45, 72–82.
10. Howell,J.J., Ricoult,S.J., Ben-Sahra,I. and Manning,B.D. (2013) A
growing role for mTOR in promoting anabolic metabolism.
Biochem. Soc. Trans., 41, 906–912.
11. Fonseca,B.D., Smith,E.M., Yelle,N., Alain,T., Bushell,M. and
Pause,A. (2014) The ever-evolving role of mTOR in translation.
Semin. Cell Dev. Biol., 36, 102–112.
12. Gingras,A.C., Raught,B. and Sonenberg,N. (2004) mTOR signaling
to translation. Curr. Top. Microbiol. Immunol., 279, 169–197.
13. Gingras,A.C., Raught,B. and Sonenberg,N. (2001) Regulation of
translation initiation by FRAP/mTOR. Genes Dev., 15, 807–826.
14. Ma,X.M. and Blenis,J. (2009) Molecular mechanisms of
mTOR-mediated translational control. Nat. Rev. Mol. Cell Biol., 10,
307–318.
15. Gingras,A.C., Gygi,S.P., Raught,B., Polakiewicz,R.D.,
Abraham,R.T., Hoekstra,M.F., Aebersold,R. and Sonenberg,N.
(1999) Regulation of 4E-BP1 phosphorylation: a novel two-step
mechanism. Genes Dev., 13, 1422–1437.
16. Gingras,A.C., Raught,B., Gygi,S.P., Niedzwiecka,A., Miron,M.,
Burley,S.K., Polakiewicz,R.D., Wyslouch-Cieszynska,A.,
Aebersold,R. and Sonenberg,N. (2001) Hierarchical
phosphorylation of the translation inhibitor 4E-BP1. Genes Dev., 15,
2852–2864.
17. Holz,M.K., Ballif,B.A., Gygi,S.P. and Blenis,J. (2005) mTOR and
S6K1 mediate assembly of the translation preinitiation complex
through dynamic protein interchange and ordered phosphorylation
events. Cell, 123, 569–580.
18. Bandi,H.R., Ferrari,S., Krieg,J., Meyer,H.E. and Thomas,G. (1993)
Identification of 40 S ribosomal protein S6 phosphorylation sites in
Swiss mouse 3T3 fibroblasts stimulated with serum. J. Biol. Chem.,
268, 4530–4533.
19. Ferrari,S., Bandi,H.R., Hofsteenge,J., Bussian,B.M. and Thomas,G.
(1991) Mitogen-activated 70K S6 kinase. Identification of in vitro 40
S ribosomal S6 phosphorylation sites. J. Biol. Chem., 266,
22770–22775.
20. Krieg,J., Hofsteenge,J. and Thomas,G. (1988) Identification of the
40 S ribosomal protein S6 phosphorylation sites induced by
cycloheximide. J. Biol. Chem., 263, 11473–11477.
21. Meyuhas,O. (2008) Physiological roles of ribosomal protein S6: one
of its kind. Int. Rev. Cell Mol. Biol., 268, 1–37.
22. Meyuhas,O. (2015) Ribosomal protein S6 phosphorylation: four
decades of research. Int. Rev. Cell Mol. Biol., 320, 41–73.
23. Wang,X., Li,W., Williams,M., Terada,N., Alessi,D.R. and
Proud,C.G. (2001) Regulation of elongation factor 2 kinase by
p90(RSK1) and p70 S6 kinase. EMBO J., 20, 4370–4379.
24. Iadevaia,V., Caldarola,S., Tino,E., Amaldi,F. and Loreni,F. (2008)
All translation elongation factors and the e, f, and h subunits of
translation initiation factor 3 are encoded by 5’-terminal
oligopyrimidine (TOP) mRNAs. RNA, 14, 1730–1736.
25. Fonseca,B.D., Lahr,R.M., Damgaard,C.K., Alain,T. and
Berman,A.J. (2018) LARP1 on TOP of ribosome production. Wiley
Interdiscipl. Rev. RNA, 9, e1480.
26. Meyuhas,O. (2000) Synthesis of the translational apparatus is
regulated at the translational level. Eur. J. Biochem., 267, 6321–6330.
27. Meyuhas,O. and Kahan,T. (2015) The race to decipher the top
secrets of TOP mRNAs. Biochim. Biophys. Acta, 1849, 801–811.
28. Avni,D., Biberman,Y. and Meyuhas,O. (1997) The 5’ terminal
oligopyrimidine tract confers translational control on TOP mRNAs
in a cell type- and sequence context-dependent manner. Nucleic
Acids Res., 25, 995–1001.
Nucleic Acids Research, 2021, Vol. 49, No. 1 477
29. Biberman,Y. and Meyuhas,O. (1999) TOP mRNAs are
translationally inhibited by a titratable repressor in both wheat germ
extract and reticulocyte lysate. FEBS Lett., 456, 357–360.
30. Levy,S., Avni,D., Hariharan,N., Perry,R.P. and Meyuhas,O. (1991)
Oligopyrimidine tract at the 5’ end of mammalian ribosomal protein
mRNAs is required for their translational control. PNAS, 88,
3319–3323.
31. Thoreen,C.C., Chantranupong,L., Keys,H.R., Wang,T., Gray,N.S.
and Sabatini,D.M. (2012) A unifying model for mTORC1-mediated
regulation of mRNA translation. Nature, 485, 109–113.
32. Hsieh,A.C., Liu,Y., Edlind,M.P., Ingolia,N.T., Janes,M.R., Sher,A.,
Shi,E.Y., Stumpf,C.R., Christensen,C., Bonham,M.J. et al. (2012)
The translational landscape of mTOR signalling steers cancer
initiation and metastasis. Nature, 485, 55–61.
33. Bortoluzzi,S., d’Alessi,F., Romualdi,C. and Danieli,G.A. (2001)
Differential expression of genes coding for ribosomal proteins in
different human tissues. Bioinformatics, 17, 1152–1157.
34. Geyer,P.K., Meyuhas,O., Perry,R.P. and Johnson,L.F. (1982)
Regulation of ribosomal protein mRNA content and translation in
growth-stimulated mouse fibroblasts. Mol. Cell. Biol., 2, 685–693.
35. Pellizzoni,L., Lotti,F., Maras,B. and Pierandrei-Amaldi,P. (1997)
Cellular nucleic acid binding protein binds a conserved region of the
5’ UTR of Xenopus laevis ribosomal protein mRNAs. J. Mol. Biol.,
267, 264–275.
36. Crosio,C., Boyl,P.P., Loreni,F., Pierandrei-Amaldi,P. and Amaldi,F.
(2000) La protein has a positive effect on the translation of TOP
mRNAs in vivo. Nucleic Acids Res., 28, 2927–2934.
37. Cardinali,B., Carissimi,C., Gravina,P. and Pierandrei-Amaldi,P.
(2003) La protein is associated with terminal oligopyrimidine
mRNAs in actively translating polysomes. J. Biol. Chem., 278,
35145–35151.
38. Fonseca,B.D., Zakaria,C., Jia,J.J., Graber,T.E., Svitkin,Y.,
Tahmasebi,S., Healy,D., Hoang,H.D., Jensen,J.M., Diao,I.T. et al.
(2015) La-related protein 1 (LARP1) represses terminal
oligopyrimidine (TOP) mRNA translation downstream of mTOR
complex 1 (mTORC1). J. Biol. Chem., 290, 15996–16020.
39. Lahr,R.M., Fonseca,B.D., Ciotti,G.E., Al-Ashtal,H.A., Jia,J.J.,
Niklaus,M.R., Blagden,S.P., Alain,T. and Berman,A.J. (2017)
La-related protein 1 (LARP1) binds the mRNA cap, blocking eIF4F
assembly on TOP mRNAs. eLife, 6, e24146.
40. Lahr,R.M., Mack,S.M., Heroux,A., Blagden,S.P.,
Bousquet-Antonelli,C., Deragon,J.M. and Berman,A.J. (2015) The
La-related protein 1-specific domain repurposes HEAT-like repeats
to directly bind a 5’TOP sequence. Nucleic Acids Res., 43,
8077–8088.
41. Tcherkezian,J., Cargnello,M., Romeo,Y., Huttlin,E.L., Lavoie,G.,
Gygi,S.P. and Roux,P.P. (2014) Proteomic analysis of cap-dependent
translation identifies LARP1 as a key regulator of 5’TOP mRNA
translation. Genes Dev., 28, 357–371.
42. Cassidy,K.C., Lahr,R.M., Kaminsky,J.C., Mack,S., Fonseca,B.D.,
Das,S.R., Berman,A.J. and Durrant,J.D. (2019) Capturing the
mechanism underlying TOP mRNA binding to LARP1. Structure
(London, England), 27, 1771–1781.
43. Philippe,L., van den Elzen,A.M.G., Watson,M.J. and Thoreen,C.C.
(2020) Global analysis of LARP1 translation targets reveals tunable
and dynamic features of 5’ TOP motifs. PNAS, 117, 5319–5328.
44. Liu,Q., Kang,S.A., Thoreen,C.C., Hur,W., Wang,J., Chang,J.W.,
Markhard,A., Zhang,J., Sim,T., Sabatini,D.M. et al. (2012)
Development of ATP-competitive mTOR inhibitors. Methods Mol.
Biol., 821, 447–460.
45. Liu,Q., Kirubakaran,S., Hur,W., Niepel,M., Westover,K.,
Thoreen,C.C., Wang,J., Ni,J., Patricelli,M.P., Vogel,K. et al. (2012)
Kinome-wide selectivity profiling of ATP-competitive mammalian
target of rapamycin (mTOR) inhibitors and characterization of their
binding kinetics. J. Biol. Chem., 287, 9742–9752.
46. Feldman,M.E., Apsel,B., Uotila,A., Loewith,R., Knight,Z.A.,
Ruggero,D. and Shokat,K.M. (2009) Active-site inhibitors of
mTOR target rapamycin-resistant outputs of mTORC1 and
mTORC2. PLoS Biol., 7, e38.
47. Oh,W.J., Wu,C.C., Kim,S.J., Facchinetti,V., Julien,L.A., Finlan,M.,
Roux,P.P., Su,B. and Jacinto,E. (2010) mTORC2 can associate with
ribosomes to promote cotranslational phosphorylation and stability
of nascent Akt polypeptide. EMBO J., 29, 3939–3951.
48. Zinzalla,V., Stracka,D., Oppliger,W. and Hall,M.N. (2011)
Activation of mTORC2 by association with the ribosome. Cell, 144,
757–768.
49. Nandagopal,N. and Roux,P.P. (2015) Regulation of global and
specific mRNA translation by the mTOR signaling pathway.
Translation (Austin, Tex.), 3, e983402.
50. Stumpf,C.R., Moreno,M.V., Olshen,A.B., Taylor,B.S. and
Ruggero,D. (2013) The translational landscape of the mammalian
cell cycle. Mol. Cell, 52, 574–582.
51. Garcı́a-Martı́nez,J.M. and Alessi,D.R. (2008) mTOR complex 2
(mTORC2) controls hydrophobic motif phosphorylation and
activation of serum- and glucocorticoid-induced protein kinase 1
(SGK1). Biochem. J., 416, 375–385.
52. Yang,H., Rudge,D.G., Koos,J.D., Vaidialingam,B., Yang,H.J. and
Pavletich,N.P. (2013) mTOR kinase structure, mechanism and
regulation. Nature, 497, 217–223.
53. Saxton,R.A. and Sabatini,D.M. (2017) mTOR signaling in growth,
metabolism, and disease. Cell, 168, 960–976.
54. Sarbassov,D.D., Guertin,D.A., Ali,S.M. and Sabatini,D.M. (2005)
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR
complex. Science, 307, 1098–1101.
55. Hresko,R.C. and Mueckler,M. (2005) mTOR.RICTOR is the
Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J.
Biol. Chem., 280, 40406–40416.
56. Facchinetti,V., Ouyang,W., Wei,H., Soto,N., Lazorchak,A.,
Gould,C., Lowry,C., Newton,A.C., Mao,Y., Miao,R.Q. et al. (2008)
The mammalian target of rapamycin complex 2 controls folding and
stability of Akt and protein kinase C. EMBO J., 27, 1932–1943.
57. Ikenoue,T., Inoki,K., Yang,Q., Zhou,X. and Guan,K.L. (2008)
Essential function of TORC2 in PKC and Akt turn motif
phosphorylation, maturation and signalling. EMBO J., 27,
1919–1931.
58. Guertin,D.A., Stevens,D.M., Thoreen,C.C., Burds,A.A.,
Kalaany,N.Y., Moffat,J., Brown,M., Fitzgerald,K.J. and
Sabatini,D.M. (2006) Ablation in mice of the mTORC components
raptor, rictor, or mLST8 reveals that mTORC2 is required for
signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev. Cell, 11,
859–871.
59. Thoreen,C.C., Kang,S.A., Chang,J.W., Liu,Q., Zhang,J., Gao,Y.,
Reichling,L.J., Sim,T., Sabatini,D.M. and Gray,N.S. (2009) An
ATP-competitive mammalian target of rapamycin inhibitor reveals
rapamycin-resistant functions of mTORC1. J. Biol. Chem., 284,
8023–8032.
60. Leek,J.T., Johnson,W.E., Parker,H.S., Jaffe,A.E. and Storey,J.D.
(2012) The sva package for removing batch effects and other
unwanted variation in high-throughput experiments. Bioinformatics,
28, 882–883.
61. Ritchie,M.E., Phipson,B., Wu,D., Hu,Y., Law,C.W., Shi,W. and
Smyth,G.K. (2015) limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res., 43,
e47.
62. Morris,K.L. (2017) Investigation of RNA binding proteins
regulated by mTOR, PhD, University of Leicester.
63. Munnur,D., Somers,J., Skalka,G., Weston,R., Jukes-Jones,R.,
Bhogadia,M., Dominguez,C., Cain,K., Ahel,I. and Malewicz,M.
(2019) NR4A Nuclear Receptors Target Poly-ADP-Ribosylated
DNA-PKcs Protein to Promote DNA Repair. Cell Rep., 26,
2028–2036.e2026.
64. Wilczynska,A., Gillen,S.L., Schmidt,T., Meijer,H.A.,
Jukes-Jones,R., Langlais,C., Kopra,K., Lu,W.T., Godfrey,J.D.,
Hawley,B.R. et al. (2019) eIF4A2 drives repression of translation at
initiation by Ccr4-Not through purine-rich motifs in the 5’UTR.
Genome biol., 20, 262.
65. Orom,U.A., Nielsen,F.C. and Lund,A.H. (2008) MicroRNA-10a
binds the 5’UTR of ribosomal protein mRNAs and enhances their
translation. Mol. Cell, 30, 460–471.
66. Bertrand,E., Chartrand,P., Schaefer,M., Shenoy,S.M., Singer,R.H.
and Long,R.M. (1998) Localization of ASH1 mRNA particles in
living yeast. Mol. Cell, 2, 437–445.
67. Garside,P. (2010) PhD, University of Nottingham.
68. Meijer,H.A., Schmidt,T., Gillen,S.L., Langlais,C., Jukes-Jones,R.,
de Moor,C.H., Cain,K., Wilczynska,A. and Bushell,M. (2019)
DEAD-box helicase eIF4A2 inhibits CNOT7 deadenylation
activity. Nucleic Acids Res., 47, 8224–8238.
478 Nucleic Acids Research, 2021, Vol. 49, No. 1
69. Hay,N. and Sonenberg,N. (2004) Upstream and downstream of
mTOR. Genes Dev., 18, 1926–1945.
70. Biberman,Y. and Meyuhas,O. (1997) Substitution of just five
nucleotides at and around the transcription start site of rat
beta-actin promoter is sufficient to render the resulting transcript a
subject for translational control. FEBS Lett., 405, 333–336.
71. Castello,A., Horos,R., Strein,C., Fischer,B., Eichelbaum,K.,
Steinmetz,L.M., Krijgsveld,J. and Hentze,M.W. (2013) System-wide
identification of RNA-binding proteins by interactome capture. Nat.
Protoc., 8, 491.
72. Sysoev,V.O., Fischer,B., Frese,C.K., Gupta,I., Krijgsveld,J.,
Hentze,M.W., Castello,A. and Ephrussi,A. (2016) Global changes
of the RNA-bound proteome during the maternal-to-zygotic
transition in Drosophila. Nat. Commun., 7, 12128.
73. Hong,S., Freeberg,M.A., Han,T., Kamath,A., Yao,Y., Fukuda,T.,
Suzuki,T., Kim,J.K. and Inoki,K. (2017) LARP1 functions as a
molecular switch for mTORC1-mediated translation of an essential
class of mRNAs. eLife, 6, e25237.
74. Gentilella,A., Moron-Duran,F.D., Fuentes,P., Zweig-Rocha,G.,
Riano-Canalias,F., Pelletier,J., Ruiz,M., Turon,G., Castano,J.,
Tauler,A. et al. (2017) Autogenous Control of 5’TOP mRNA
Stability by 40S Ribosomes. Mol. Cell, 67, 55–70.
75. Philippe,L., Vasseur,J.J., Debart,F. and Thoreen,C.C. (2018)
La-related protein 1 (LARP1) repression of TOP mRNA translation
is mediated through its cap-binding domain and controlled by an
adjacent regulatory region. Nucleic Acids Res., 46, 1457–1469.
76. Haneke,K., Schott,J., Lindner,D., Hollensen,A.K., Damgaard,C.K.,
Mongis,C., Knop,M., Palm,W., Ruggieri,A. and Stoecklin,G. (2020)
CDK1 couples proliferation with protein synthesis. J. Cell Biol., 219,
e201906147.
77. Al-Ashtal,H.A., Rubottom,C.M., Leeper,T.C. and Berman,A.J.
(2019) The LARP1 La-Module recognizes both ends of TOP
mRNAs. RNA Biol., doi:10.1080/15476286.2019.1669404.
78. Kwon,S.C., Yi,H., Eichelbaum,K., Fohr,S., Fischer,B., You,K.T.,
Castello,A., Krijgsveld,J., Hentze,M.W. and Kim,V.N. (2013) The
RNA-binding protein repertoire of embryonic stem cells. Nat.
Struct. Mol. Biol., 20, 1122–1130.
79. Sanchez,J.G., Sparrer,K.M.J., Chiang,C., Reis,R.A., Chiang,J.J.,
Zurenski,M.A., Wan,Y., Gack,M.U. and Pornillos,O. (2018)
TRIM25 binds RNA to modulate cellular anti-viral defense. J. Mol.
Biol., 430, 5280–5293.
80. Williams,F.P., Haubrich,K., Perez-Borrajero,C. and Hennig,J.
(2019) Emerging RNA-binding roles in the TRIM family of
ubiquitin ligases. Biol. Chem., 400, 1443–1464.
81. Choudhury,N.R., Heikel,G., Trubitsyna,M., Kubik,P., Nowak,J.S.,
Webb,S., Granneman,S., Spanos,C., Rappsilber,J., Castello,A. et al.
(2017) RNA-binding activity of TRIM25 is mediated by its
PRY/SPRY domain and is required for ubiquitination. BMC Biol.,
15, 105.
82. Brown,A., Baird,M.R., Yip,M.C., Murray,J. and Shao,S. (2018)
Structures of translationally inactive mammalian ribosomes. eLife,
7, e40486.
83. Muto,A., Sugihara,Y., Shibakawa,M., Oshima,K., Matsuda,T. and
Nadano,D. (2018) The mRNA-binding protein Serbp1 as an
auxiliary protein associated with mammalian cytoplasmic
ribosomes. Cell Biochem. Funct., 36, 312–322.
84. Anger,A.M., Armache,J.P., Berninghausen,O., Habeck,M.,
Subklewe,M., Wilson,D.N. and Beckmann,R. (2013) Structures of
the human and Drosophila 80S ribosome. Nature, 497, 80–85.
85. Boissier,F., Schmidt,C.M., Linnemann,J., Fribourg,S. and
Perez-Fernandez,J. (2017) Pwp2 mediates UTP-B assembly via two
structurally independent domains. Sci. Rep., 7, 3169.
86. Dosil,M. and Bustelo,X.R. (2004) Functional characterization of
Pwp2, a WD family protein essential for the assembly of the 90 S
pre-ribosomal particle. J. Biol. Chem., 279, 37385–37397.
87. Chauvin,C., Koka,V., Nouschi,A., Mieulet,V., Hoareau-Aveilla,C.,
Dreazen,A., Cagnard,N., Carpentier,W., Kiss,T., Meyuhas,O. et al.
(2014) Ribosomal protein S6 kinase activity controls the ribosome
biogenesis transcriptional program. Oncogene, 33, 474–483.
88. Nelson,E.M. and Winkler,M.M. (1987) Regulation of mRNA entry
into polysomes. Parameters affecting polysome size and the fraction
of mRNA in polysomes. J. Biol. Chem., 262, 11501–11506.
89. Mili,S. and Steitz,J.A. (2004) Evidence for reassociation of
RNA-binding proteins after cell lysis: implications for the
interpretation of immunoprecipitation analyses. RNA, 10,
1692–1694.
90. Marzluff,W.F., Wagner,E.J. and Duronio,R.J. (2008) Metabolism
and regulation of canonical histone mRNAs: life without a poly(A)
tail. Nat. Rev. Genet., 9, 843–854.
91. Kudla,M. and Karginov,F.V. (2016) Measuring mRNA Translation
by Polysome Profiling. Methods Mol. Biol., 1421, 127–135.
92. Burrows,C., Abd Latip,N., Lam,S.J., Carpenter,L., Sawicka,K.,
Tzolovsky,G., Gabra,H., Bushell,M., Glover,D.M., Willis,A.E. et al.
(2010) The RNA binding protein Larp1 regulates cell division,
apoptosis and cell migration. Nucleic Acids Res., 38, 5542–5553.
93. Kahvejian,A., Svitkin,Y.V., Sukarieh,R., M’Boutchou,M.N. and
Sonenberg,N. (2005) Mammalian poly(A)-binding protein is a
eukaryotic translation initiation factor, which acts via multiple
mechanisms. Genes Dev., 19, 104–113.
94. Costello,J., Castelli,L.M., Rowe,W., Kershaw,C.J., Talavera,D.,
Mohammad-Qureshi,S.S., Sims,P.F., Grant,C.M., Pavitt,G.D.,
Hubbard,S.J. et al. (2015) Global mRNA selection mechanisms for
translation initiation. Genome Biol., 16, 10.
95. Sawazaki,R., Imai,S., Yokogawa,M., Hosoda,N., Hoshino,S.I.,
Mio,M., Mio,K., Shimada,I. and Osawa,M. (2018) Characterization
of the multimeric structure of poly(A)-binding protein on a poly(A)
tail. Sci. Rep., 8, 1455.
96. Maraia,R.J., Mattijssen,S., Cruz-Gallardo,I. and Conte,M.R. (2017)
The La and related RNA-binding proteins (LARPs): structures,
functions, and evolving perspectives. Wiley Interdiscipl. Rev. RNA, 8,
e1430.
97. Martino,L., Pennell,S., Kelly,G., Busi,B., Brown,P., Atkinson,R.A.,
Salisbury,N.J., Ooi,Z.H., See,K.W., Smerdon,S.J. et al. (2015)
Synergic interplay of the La motif, RRM1 and the interdomain
linker of LARP6 in the recognition of collagen mRNA expands the
RNA binding repertoire of the La module. Nucleic Acids Res., 43,
645–660.
98. Marzluff,W.F. (2005) Metazoan replication-dependent histone
mRNAs: a distinct set of RNA polymerase II transcripts. Curr.
Opin. Cell Biol., 17, 274–280.
99. Yoon,M.S. (2017) The role of mammalian target of rapamycin
(mTOR) in insulin signaling. Nutrients, 9, e1176.
100. To,T.L., Cuadros,A.M., Shah,H., Hung,W.H.W., Li,Y., Kim,S.H.,
Rubin,D.H.F., Boe,R.H., Rath,S., Eaton,J.K. et al. (2019) A
compendium of genetic modifiers of mitochondrial dysfunction
reveals intra-organelle buffering. Cell, 179, 1222–1238.
101. Zhang,Y. and Xu,H. (2016) Translational regulation of
mitochondrial biogenesis. Biochem. Soc. Trans., 44, 1717–1724.
102. Zhang,Y., Wang,Z.H., Liu,Y., Chen,Y., Sun,N., Gucek,M., Zhang,F.
and Xu,H. (2019) PINK1 inhibits local protein synthesis to limit
transmission of deleterious mitochondrial DNA mutations. Mol.
Cell, 73, 1127–1137.
103. Perez-Riverol,Y., Csordas,A., Bai,J., Bernal-Llinares,M.,
Hewapathirana,S., Kundu,D.J., Inuganti,A., Griss,J., Mayer,G.,
Eisenacher,M. et al. (2019) The PRIDE database and related tools
and resources in 2019: improving support for quantification data.
Nucleic Acids Res., 47, D442–D450.
104. Edgar,R., Domrachev,M. and Lash,A.E. (2002) Gene Expression
Omnibus: NCBI gene expression and hybridization array data
repository. Nucleic Acids Res., 30, 207–210.
